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Effect of Certain Formulation Factors on the Dissolution and 
Absorption of Drugs.
Director: M. Wafik Gouda —
The rate of absorption of poorly soluble drugs is dissolution 
rate-limited. Slow dissolution results in incomplete, erratic 
and unpredictable absorption. Two methods of increasing the dis­
solution of two categories of drugs were investigated.
1. The effect of two medicinally used surfactants, poloxalene and 
dioctylsodium sulfosuccinate, on the dissolution of the sulfona­
mides, sulfisoxazole and sulfadiazine was studied. A dramatic 
increase in the dissolution rate of both the drugs was noted in 
the presence of all concentrations of the surfactants. A signi­
ficant but less dramatic increase in the absorption of these 
drugs was brought about by the surfactants.
2. Solid dispersions, 1 and 10% w/w of the cardiac glycosides 
digitoxin and digoxin in two inert carriers, poloxalene and 
deoxycholic acid, were prepared. All the solid dispersions 
dissolved significantly faster than the pure drugs. In all 
cases, the 1% solid dispersions dissolved at a faster rate than 
the 10% solid dispersions. As an indication of bioavailability, 
the toxicity of the different preparations in mice was evaluated. 
The 10% digitoxin solid dispersions in both the carriers showed
a significantly higher toxicity than the drug alone indicating 
an increase in the bioavailability of the solid-dispersed drug.
The nature of solid dispersions obtained was studied by the 
x-ray diffraction technique.
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PART ONE 
SULFONAMIDES
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CHAPTER I 
INTRODUCTION
The biological availability of a drug is the result of many 
processes. Low solubility and slow dissolution are only two of many 
factors which contribute to poor availability. In order for an orally 
administered solid drug to be absorbed, it must first dissolve in the 
aqueous environment of the gastrointestinal tract. An aqueous solubil­
ity of less than 1% at 37® over a pH range of 1 to 7 suggests potential 
problems in the absorption of a drug. Noyes and Whitney (82) quantita­
tively studied dissolution and derived the following equation: 
dA
3#  = k(Cs-c) CD
where A is the concentration at time t, and Cg is the equilibrium solu­
bility of the solute at the experimental temperature.
In later studies surface area of the dissolving material was 
incorporated to give: 
dA^  = K S(Cg-C) (2)
Brunner (16) used Pick's law of diffusion to establish a relationship 
between the constant in the above equation and the diffusion coefficient 
of the solute.
It is apparent from equation 2 that the dissolution kinetics are 
subject to many influences. From a pharmaceutical point of view, the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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factor which can be manipulated with the least difficulty to increase 
dissolution rate is the surface area of the drug. Sulfadiazine was one 
of the first drugs whose absorption was shown to be dependent on par­
ticle size. Not only was the drug absorbed at a faster rate from the 
smaller particles but also the total amount of the dose absorbed was 
greater. Takubo et al (111) found that the absorption of sulfanilamide 
and sulfisoxazole from the rabbit rectum and intestine was influenced 
by particle size. The absorption rate constant was proportional to the 
log of the reciprocal of the particle size and the dissolution rate
constant was proportional to the reciprocal of particle size.
' »
There are a number of other reported studies (33, 112) showing 
that the absorption of sulfonamides is related to the dissolution rate 
of drugs or their dosage forms. The dissolution rate of a drug can be 
increased by increasing its effective surface area, which is the area 
in actual contact with the dissolution medium. For hydrophobic materials 
the effective surface area may be drastically smaller than the specific 
area. IVhen the particle size of a hydrophobic drug is reduced, the in­
crease in effective surface area might not be anywhere close to the in­
crease in its specific surface area. This is because of the fact that 
with an increase in surface area, there is a corresponding increase in 
surface energy which causes the fine particles to adhere to each other 
and form larger particles.
Effective surface area can also be increased without reducing 
the particle size, by incorporating certain adjuvants in the dosage 
form. These adjuvants are called surface active agents, surfactants, 
or association colloids. They are compounds which, while soluble in a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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given liquid, tend to accumulate or be positively adsorbed at its inter­
faces with air, another liquid, or a solid. A single surfactant molecule 
contains one or more hydrophobic portions and one or more hydrophilic 
groups. Depending on the hydrophilic moiety, these compounds are called, 
anionic, cationic, or nonionic.
Surface active agents increase the dissolution rate of poorly 
soluble drugs by decreasing the interfacial tension between the drug and 
the dissolution medium, thus allowing the latter to wet the drug more 
completely, or by means of micellar solubilization. The latter mechanism 
is prominent only in concentrations above the critical micelle concentra­
tion CCMC). Though a number of studies dealing with the effect of high 
concentrations (above CMC) of surfactants on drug absorption have been 
reported, their effect in low concentrations have not been widely studied.
Dioctylsodium sulfosuccinate (DOSS) and poloxalene are two sur­
factants which are commonly used in medicine. The effect of these two 
surface active agents on absorption through various types of membranes 
have been previously reported (45, 46, 55, 70). This study was under­
taken to determine the effect of DOSS and poloxalene on the dissolution 
and absorption of the two sulfonamides, sulfisoxazole and sulfadiazine. 
The data generated could help in determining which of the two surfactants 
would be a better choice for incorporation in a suspension dosage form.
LITERATURE SURVEY 
Mechanisms of Surfactant Effects on Drug Absorption
Surface active agents are used internally or externally in almost 
every dosage form, including liquids, semisolids, and solids. They are
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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included in pharmaceutical preparations to act as wetting agents, dis­
persing agents, foaming agents, emulsifying agents, etc. There are 
reports indicating that surface active agents increase as well as de­
crease the absorption of drugs, Blanpin (14) reviewed many of these 
reports. As Levy (60) has pointed out, much of the difficulty in anal­
yzing these studies is because of the different types of effects these 
agents exert. They may exert their effect on the biological membrane 
and modify its permeability to drugs, they may interact with the drug 
or the dosage form or with the organism itself, exerting pharmacological 
effects of their own. This in turn might affect drug absorption. To 
complicate matters further, these effects might be operative at the same 
time, some of which may affect drug absorption in the positive manner 
and others in a negative manner. The net effect in such a case will 
depend on the relative magnitude of each.
Effect of Surfactants on Solubility and Dissolution Rate of Drugs
Those drugs whose absorption is dissolution rate-limited are the 
ones which can be influenced most by surface active agents. Two impor­
tant parameters determining the dissolution rate of a drug are its 
solubility in the dissolution medium and the surface area of the drug 
exposed to the dissolution medium. When the particle size is greater 
than about 10 y, the rate of dissolution is directly proportional to the 
surface area. In this case, surface area, and not particle size per se, 
is a factor controlling dissolution rate. The initial rate of dissolu­
tion, i.e., the rate at very low percentage saturations of the dissolu­
tion medium, is directly proportional to the solubility of the drug in 
the dissolution medium.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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When the surface area of a drug is increased by particle size 
reduction, there is also a considerable increase in the surface free 
energy. The hydrophobic properties of the fine particles are increased 
because of adsorption of air. The relative magnitude of the interpar­
ticulate binding force, such as electrostatic charge is also increased, 
which leads to clunking. These clumps, called aggregates or agglomer­
ates, are..much larger in size than the individual particles. The dis­
solution rate is thus decreased instead of being increased due to 
micronization (67). The presence of a surface active agent in the dis­
solving medium prevents the fine particles from forming aggregates by 
improving the wetting of the particles. Because of wetting, the fluid 
surrounds the individual particles, displacing the air around them, and 
a fast dissolution rate results. The dissolution rate of aspirin powder 
was found to be inversely proportional to the crystal size, but the 
opposite was found true in tablets (27). This was reported to be due to 
the agglomeration of fine particles and it could be hindered by appro­
priate adjuvants.
In a dissolution study (115), cylindrical compressed tablets 
containing large pores were used to follow the dissolution process.
When distilled water was used as the dissolution medium, the surface 
area of the pores was incompletely exposed to the solvent due to occlu­
sion by air. When the surface tension of the dissolution medium was 
decreased, an increase in the dissolution rate was noted, because of 
better wetting of the surface. Similar effects were noted when the air 
was evacuated from the pores.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7
Premicellar concentrations of polyoxyethylene lauryl ether and 
lysoleclthin (113) were found to enhance the dissolution rate of sali­
cylic acid powder. The same surfactants also increased the dissolution 
rate of aspirin from a tablet dosage form but had no effect on the dis­
solution rate of the drug from a capsule. A good correlation was ob­
tained between the surface tension of the polyoxyethylene lauryl ether 
Solutions and the dissolution rates of aspirin from the tablets. Short 
et al (98) investigated the effect of low concentrations of an n-alkyl 
polyoxyethylene surfactant on the dissolution of hydrocortisone. It was 
shown that the plot of the dissolution rate constant versus the surfac­
tant concentration exhibited a maxima in the region of the CMC. Finholt 
and Solvang (34) studied the dissolution of phenacetin powder in 0.1 
N hydrochloric acid containing various concentrations of polysobate 80. 
Increasing the surfactant concentration from 0 to 0.01% caused a signi­
ficant increase in the dissolution rate. Beyond 0.01% and up to 0.2%, 
little change in dissolution rate was observed. The surface tension of 
the dissolution medium was shown to have an appreciable effect on the 
dissolution kinetics of the drug.
’Solubilization' is the term used to describe the manner in 
which surface active agents increase the solubility of a material in a 
given solvent. McBain (76) described solubilized systems as those in 
which the solubility of materials otherwise insoluble, or only poorly 
soluble, in a given media, is increased due to the prior presence of 
particles of colloidal dimensions, called micelles.
Wurster and Seitz (115) showed an increased solubility of ben­
zoic acid at 0.2% concentration of sodium lauryl sulfate. As has been
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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shown by other workers (30, 49, 80) solubilization of some materials may 
be brought about in concentrations of surfactants well below their CMC.
Micellar solutions of the bile salts, sodium cholate and sodium 
deoxycholate enhanced the dissolution rate of griseofulvin and hexestrol. 
The enhancement in the dissolution rates of these two drugs in the pre­
sence of the bile salts was most probably due to a lowering of the inter­
facial tension between the drug and the dissolution medium as well as 
micellar solubilization. The authors (9) suspected that since the con­
centrations of the bile salts used was about four times their CMC values, 
solubilization might have played a greater role. Physiological concen­
trations of lysolecithin (10) produced marked increases in the solubil­
ity and dissolution rate of hexestrol, dienestrol, and griseofulvin.
Parrot and Sharma (84) studied the dissolution of benzoic acid 
from constant surface tablets in aqueous solutions of four surfactants-- 
tyloxapol, polysorbate 80, sodium lauryl sulfate, and poloxalkol (polox­
alene). A linear relationship between solubilization of benzoic acid 
and concentration of the surface active agents was found to exist. At 
concentrations of these surface active agents less than the CMC, the 
dissolution rate was only slightly increased due to improved wetting of 
the drug surface. At concentrations exceeding the CMC, the dissolution 
rate was increased to a maximal rate by an increase in concentration of 
tyloxapol, sodium lauryl sulfate and polysorbate 80. At higher concen­
trations, the dissolution rate decreased. The dissolution rate of ben­
zoic acid was retarded by poloxalkol. Elworthy and Libscomp (31) 
studied the dissolution of griseofulvin in water and in aqueous solutions
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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of four nonionic surfactants. They found that the surfactants increased 
the dissolution rate of the drug.
Kellner et al (54) found that feeding cholesterol to rabbits 
along with polysorbate 80 yielded blood levels of cholesterol two to 
three times as high as those obtained when feeding cholesterol alone.
The authors suggested better émulsification of the drug in the presence 
of the surfactant as the reason for increased absorption but it might 
well have been due to increased solubility and dissolution rate of the 
water-insoluble cholesterol brought about by polysorbate 80. Fuchs and 
Ingelfinger (35) found that sodium lauryl sulfate hastened the appear- 
ance and increased the levels of vitamin A in the blood of human subjects. 
Krause (56) found that sodium lauryl sulfate incorporated into the pills 
of G-strophanthin increased the absorption of the drug in dogs, guinea 
pigs, rabbits, and cats. The observed effect in both these studies was 
postulated to be due to the increased solubility and higher rate of dis­
solution of the drug in the presence of the surfactant. The gastroin­
testinal absorption of spironolactone was markedly improved when the drug 
was administered with polysorbate 80. It might have been due to the 
solubilization and wetting effect of the surfactant (36).
Kakemi et al (52) found that the one hour blood level of sulfi­
soxazole, after rectal administration of the drug as suspension contain­
ing varying amounts of surfactant, increased with increasing concentra­
tions of the surfactant up to a maximum of 20%. This concentration of 
the surfactant completely solubilized the excess drug. It was found 
that an eighteen fold increase in drug solubility in the presence of 
20% surfactant resulted in a threefold increase in the initial blood 
level.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Bean and Berry (11) reviewed the work on antimicrobial activity 
of solubilized products. The same authors studied the antimicrobial 
activity of benzyl chlorophenol and chloroxylenol in aqueous potassium 
laurate solutions of constant surfactant/phenol ratio (12, 13). Below 
the CMC, the activity increased due to a reduction in surface tension 
and an increase in phenol concentration. Above the CMC, the activity 
decreased because the phenol is now distributed between the aqueous 
phase and the micellar pseudophase. It is now known that the degree of 
saturation of the aqueous phase rather than the concentration in the mi­
cellar pseudophase determines the activity of a drug. Solubilization of 
salicylic acid (66), normally a well absorbed substance, decreased the 
activity of the drug due to decreased absorption. The effect of surfac­
tants seems therefore to be related to the aqueous solubility of the 
drug, and, as a consequence, its distribution between the aqueous and 
micellar phases.
The time for which a drug remains in the stomach and the rate at 
which it traverses the gastro intestinal tract are important determin­
ants of the overall rate and extent of drug absorption. Some of the 
mechanisms by which surfactants can alter gastrointestinal motility and 
gastric emptying have been studied by many workers (64, 83, 69, 93, 32, 
51, 74).
Surface active agents are capable of exerting a direct action on 
membranes, thereby modifying their permeability characteristics. Various 
authors have studied this aspect: (3, 65, 61, 6, 40, 114). Depending
on the nature and extent of drug-surfactant interaction the absorption 
of drugs may be altered by surfactants. Many authors have reported such 
findings: (90, 91, 92, 66, 52, 116).
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OBJECTIVES OF RESEARCH
The absorption of some sulfonamides from suspensions has been 
shown to depend on particle size. For example, sulfadiazine, when given 
as a microcrystalline suspension was absorbed more rapidly and to a 
greater extent than from a preparation of larger particles, with a sur­
face area about 1/7 of the microcrystalline drug. Moreover, the absorp­
tion was more uniform, i.e., there was less variation between subjects, 
with the fine particle suspension (88). Similar results were obtained 
by Boyd and Dingwall (15), who studied the absorption of sulfadiazine 
from tablets made of conventional size material, a micronized drug sus­
pension and a suspension of microcrystalline drug somewhat smaller in 
size than the micronized particles. This effect of particle size is due 
largely to the increased dissolution rate in the gastrointestinal tract. 
Since the dissolution of a drug can also be increased by increasing the 
effective surface area and since surface active agents are known to 
cause this, the present study was undertaken with the following in mind:
1. To determine the effect of two medicinal surfactants, poloxalene 
and dioctylsodium sulfosuccinate, on the dissolution of sulfadiazine 
and sulfisoxazole, and,
2. To determine the effect of these surfactants on the absorption of 
the above drugs from rat gastrointestinal tract.
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CHAPTER II 
EXPERIMENTAL 
Materials
Sulfadiazine, U.S.P., Matheson, Coleman and Bell,
Sulfisoxazole, U.S.P., Hoffman LaRoche, New Jersey.
Dioctyl Sodium Sulfosuccinate, (DOSS), Aerosol OT 100%, Sargent Welch 
Scientific Company, Illinois.
Poloxalene, 'Pluronic F 68’, Wyandotte Chemicals, Michigan.
Procedures
Intestinal Loop Technique. Male Sprague Dawley rats (supplied by Horton 
Labs., California) weighing between 200 and 300 gm were starved for 
16-18 hours before the experiment, with water allowed ad libitum. The 
rats were anesthetized with ether and a midline incision was made to 
expose the abdominal cavity. The peritoneal cavity was hydrated with 
5 ml normal saline. The ileocecal end of the intestine was ligated and 
a loose ligature placed about 2 cm proximal to the first. A small inci­
sion was made between the two ligatures. About 2 cm distal to the 
pyloric end of the intestine a small incision was made and a hypodermic 
needle with a blunt end was inserted in the opening and secured tightly 
with a silk suture. Fifty milliliter normal saline, warmed to 37°, was 
injected through a hypodermic needle, very slowly, to clear the intestine
12
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of particulate matter and the washings collected at the opening near the 
ileocecal end. Ten minutes after the washing, the ligature at the 
ileocecal end was tightened. The drug was administered through the 
hypodermic needle as a suspension in 3.5 ml of water containing varying 
concentrations of either of the surfactants. The needle was immediately 
pulled out, tightening the ligature simultaneously so that the drug sus­
pension did not flow out. The abdominal cavity was closed with sutures 
and the anesthetic removed. Three hours after the administration of 
sulfadiazine or a half hour after sulfisoxazole, the animals were sac­
rificed with ether and the whole intestinal loop excised.
Analysis of Drug in the Intestinal Loop. The intestinal loop was placed 
in a blender and homogenized with 10 ml of 0.1 N sodium hydroxide for 
2 minutes. The blender was then washed with water and the washings com­
bined and volume made up to 100 ml. An aliquot of the homogenate was 
centrifuged at 5000 r.p.m. for 10 minutes. Ten milliliter of the super­
natant liquid was added to 10 ml of 35% w/v trichloroacetic acid, mixed 
by inversion, and recentrifuged. The supernate was filtered and 10 ml 
of the filtrate was transferred to a 100 ml volumetric flask. To the 
flask was added, in succession, at 6 minute intervals, 10 ml each of 
0.1% sodium nitrite (freshly prepared), 0.5% ammonium sulfamate and 
0.1% N-l-naphthyl ethylene diamine dihydrochloride (NEDD) in 0.125 N HCl. 
The flask was swirled after addition of each reagent to ensure proper 
mixing. The volume was made up with water and the absorbance read at 
530 nm for sulfadiazine and at 533 nm for sulfisoxazole. The pH of the 
final solution was always between 1.3 and 1.4. It was reported by Dux
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and Rosenblum (29) that in the final pH range of 1.0 to 1.6, the solu­
tion exhibited greatest optical density and minimum pH sensitivity. In 
all analyses, a Beckman ACTA G U I  spectrophotometer was used.
Drug Recovery. To see if there was any effect of the surfactants on 
drug recovery, the following study was performed: After exposing the
intestine and making a loop, the animal was sacrificed in an ether tank 
and the drug suspension in water or surfactant solution was injected. 
After a period of time (half hour for sulfisoxazole and three hours for 
sulfadiazine) the loop was excised and analyzed for drug content. A 
mean recovery of 100% was obtained in the presence and absence of the 
surfactants.
Urinary Excretion Studies. Male Sprague Dawley rats weighing between 
200 and 300 gm were starved 16-18 hours prior to the experiment, water 
allowed ad libitum. The experiments were performed in a cross over 
fashion such that each animal served as its own control. Six animals 
were used for each concentration of the two surfactants. In each group 
of six animals, three received the drug with surfactant first and the 
other three received plain drug first. A recovery period of three days 
was allowed before the crossover. The drug was administered as a sus­
pension by gastric intubation. The animals were then returned to indi­
vidual metabolic cages and their urine collected for the next 24 hours. 
During this period, solid food was withheld.
Analysis for Sulfisoxazole in the Urine. The total (free as well as 
acetylated) sulfisoxazole excreted in the urine in 24 hours was deter­
mined by the modified Bratton and Marshall method (29). The urine was
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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diluted to 100 ml with water and 10 ml of it transferred to a 100 ml 
volumetric flask to which 10 ml of 0.5 N hydrochloric acid was added.
The mixture was heated in a steam bath for one hour. After cooling,
5 ml of 0.5 N hydrochloric acid was added. Then 10 ml each of the fol­
lowing reagents, in succession at 6 minute intervals, was added: 0.1%
sodium nitrite, 0.5% ammonium sulfamate and 0.1% NEDD (in 0.125 N HCl).
The volume was made up with water and an aliquot filtered through a 
Millipore and its absorbance determined against a blank at 533 nm. The 
final pH was always between 1.3 and 1.4. It was found that the acid 
present in the dye solution and an additional 5 ml of 0.5 N HCl added 
before initiating the coupling gave a final pH in the desired range of 
1.3 to 1.4.
Preparation of Drug Suspension. The dosing volume for both the intes­
tinal loop studies and the intact rat studies was held constant at 3.5 
ml. Eleven milligrams of drug was weighed in a dry syringe and the 3.5 
ml fluid was used in portions to administer as much of the drug as pos­
sible. After administering the drug, the syringe was washed with 0.2 
Molar, pH 7.5 phosphate buffer for sulfisoxazole or with 0.1 N hydro­
chloric acid in the case of sulfadiazine and the washings suitably 
diluted. The absorbance was read at 252 nm for sulfisoxazole and at 
240 nm for sulfadiazine and the amount of drug remaining in the syringe 
calculated from a Beer’s Law plot. The exact amount of drug adminis­
tered to each animal was thus determined by subtracting the amount left 
in the syringe from that originally weighed.
Solubility Studies. Excess of drug (100 mg) was placed in Erlenmeyer 
flasks together with 25 ml of 0.5 Molar, pH 6 phosphate buffer containing
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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varying concentrations of either of the surfactants. The flasks were 
tightly stoppered and equilibrated in a Metabolyte water bath shaker main­
tained at 37*. Equilibrium solubility was determined by repetitive 
sampling. The amount of drug dissolved was determined spectrophotomet- 
rically.
Dissolution Studies. Dissolution rates were determined by the beaker 
method of Levy (63) with slight modifications.
A 80/100 mesh powder was used. The dissolution medium consisted 
of 500 ml of 0.5 Molar, pH 6 phosphate buffer containing varying concen­
trations of the surfactants. A one-liter beaker was kept in a constant 
temperature water bath (37 ± 0.1*) and a 3-blade, 1-3/4 inch diameter 
polyethylene stirrer (No. 6160, Nalge Company) centered and its height 
adjusted so that when the dissolution medium was added it would dip 
3.5 cm in the liquid. Sulfisoxazole (5 gm) or sulfadiazine (2 gm) was 
added to the beaker and the fluid, warmed to 37*, was poured along the 
walls of the beaker. Before the addition of the fluid, the stirrer was 
set to rotate at a speed of 60 r.p.m. by means of a variable speed over­
head motor. At frequent time intervals 2 ml of the dissolution medium 
was pipeted out and filtered through a Millipore filter (0.45 v pore 
size) into a flask kept at 37* to prevent possible crystallization of 
the drug. Two milliliters of fresh dissolution medium was immediately 
added to the beaker to maintain the volume constant. The amount of drug 
in solution at various time intervals was determined spectrophotometri- 
cally at 252 nm in a pH 7.5 phosphate buffer for sulfisoxazole and at 
240 nm in 0.1 N hydrochloric acid for sulfadiazine. All dissolution 
rate experiments were performed at least in duplicate. A cumulative
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correction was made for the previously removed samples in determining 
the total amount dissolved at a particular time by using the formula:
^  " ^'n'meas. (Cs,meas.)meas. 500
s+1
where Cn,meas. denotes the spectrophotometrically measured concentration, 
and Cjj is the concentration of the n^h sampling expected in the medium 
if the previous samples had not been removed.
The amount of surfactants present did not interfere with the 
assay for the drug.
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CHAPTER III
RESULTS AND DISCUSSION
Effect of DOSS and Poloxalene on the Dissolution and Solubility of Sul- 
fisoxazole and Sulfadiazine. Figures 1 and 2 illustrate the effect of 
poloxalene on the dissolution behavior of sulfadiazine and sulfisoxazole 
respectively. The presence of the surfactant in the dissolution medium 
in all concentrations studied, caused a significant increase in the dis­
solution rate of both the drugs. In the case of sulfadiazine (Fig. 1), 
as the concentration of poloxalene is increased from 0.001 to 0.1%, 
there is a distinct increase in the dissolution rate. In the case of 
sulfisoxazole (Fig. 2), an increase in the surfactant concentration from 
0.001 to 0.1% resulted in an initial increase in the dissolution of the 
drug. However, after about 3 minutes, sulfisoxazole dissolved to a 
greater extent in 0.01% than in 0.1% solution of the surfactant. This 
slight decrease in dissolution at the higher surfactant concentration 
could be the result of particle aggregation.
The dissolution behavior of sulfadiazine in the presence of DOSS 
is shown in Figure 3. DOSS in all concentrations studied significantly 
enhanced the dissolution of the drug. Increasing the concentration of 
the surfactant from 0.001 to 0.1% had almost no effect on the drug's 
dissolution.
18
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Figure 4 shows the dissolution behavior of sulfisoxazole in the 
presence of various concentrations of DOSS. As the surfactant concen­
tration was increased, there was also an increase in the dissolution of 
the drug. The increased dissolution was not limited only to the initial 
stages of the experiment, but was seen throughout the 30 minute period.
The solubility of sulfadiazine in pH 6 phosphate buffer is 
13 mg/100 ml. In the presence of 0.001, 0.01 and 0.1% of either of the 
surfactants, the solubility was increased only slightly, to 13.5 mg/100 
ml. The solubility of sulfisoxazole in plain buffer and in the presence 
of all concentrations of the two surfactants is 242.4 mg/100 ml. Sur­
face active agents generally increase the solubility of a drug only 
when they are present in concentrations above their CMC.
Since micellar solubilization is ruled out by the results ob­
tained in the solubility studies, the enhanced dissolution of the two 
sulfonamides in the presence of the surfactants must be due to better 
wetting of the drug particles by the dissolution fluid. Surface active 
agents are known to reduce the interfacial tension between the drug and 
the dissolution medium. This lowering of interfacial tension increases 
the effective surface area of the drug (34, 67, 62) which results in 
faster dissolution.
Absorption Studies
Effect of DOSS and Poloxalene on the Absorption of Sulfadiazine and 
Sulfisoxazole from Rat Intestinal Loops. The absorption of sulfisoxa­
zole from rat intestinal loops and the effect of poloxalene and DOSS on 
this process are presented in Tables I through VII. The presence of
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TABLE I
Absorption of Sulfisoxazole from 
Rat Intestinal Loops in the 
Absence of any Surfactant
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 10.4 4.7 45.0
2 9.2 4.3 46.6
3 9.9 5.0 50.7
4 8.8 3.0 34.2
5 8.0 3.4 42.7
6 9.3 4.9 52. 3
Mean - 45.25
Standard Deviation - 6.5
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TABLE II
Effect of 0.01% Poloxalene on the Absorption of 
Sulfisoxazole from Rat Intestinal Loops
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 10.2 6.4 62.5
2 10.1 5.6 55.4
3 10.4 5.6 54.1
4 10.2 5.6 54.3
5 10.2 5.2 51.5
6 10.3 6.0 58.8
Mean - 56 
Standard 
t* + 3.5
. 1
Deviation - 3.9 
(Significantly different from control at p <.01)
*2-sampIe t test
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TABLE III
Effect of 0.1% Poloxalene on the Absorption of 
Sulfisoxazole from Rat Intestinal Loops
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 10.8 4.7 43.4
2 10.6 4.9 46.3
3 10.2 6.7 65.7
4 10.2 6.8 66.5
5 9.8 5.7 57.9
6 9.9 6. 3 63.8
Mean - 57.27
Standard Deviation - 10.1
t* = 2.4496 (Significantly different from control at p <.05)
*2-sample t test
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TABLE IV
Effect of 1.0% Poloxalene on the Absorption of 
Sulfisoxazole from Rat Intestinal Loops
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 10.4 5.8 56.0
2 10.3 5.1 50.0
3 10.4 7.3 69.8
4 10.4 7.4 71.1
5 10.4 5.3 51.3
6 10.2 5.6 54.5
Mean - 58.78
Standard Deviation - 9.3
t* = 2.9250 (Significantly different from control at p <.02)
^2-sample t test
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TABLE V
Effect of 0.01% DOSS on the Absorption of
Sulfisoxazole from Rat Intestinal Loops
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 9.8 5.1 52.3
2 8.2 4.9 59.6
3 9.2 6.4 70.1
4 9.8 4.8 48.6
5 10.1 4.5 44.9
6 10.0 4.8 48.0
Mean - 53.92
Standard Deviation - 9.4
t* = 1.8600 (Significantly different from control at p <.10)
*2~sample t test
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TABLE VI
Effect of 0.1% DOSS on the Absorption of
Sulfisoxazole from Rat Intestinal Loops
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 10.9 7.2 65.9
2 10.7 6.9 64.3
3 10.7 5.9 54.5
4 10.8 4.9 45.2
5 10.9 5.5 50.4
6 10.9 5.4 49.7
Mean - 55.0
Standard Deviation - 8.4
t* = 2.2552 (Significantly different from control at p <.05)
*2-sample t test
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TABLE VII
Effect of 1.0% DOSS on the Absorption of
Sulfisoxazole from Rat Intestinal Loops
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 10.4 4.4 42.5
2 10.5 4.6 43.9
3 10.5 4.7 44.6
4 10.5 5.6 53,5
5 10.5 4.8 46.0
6 10.4 6.4 60.9
Mean - 48.57
Standard Deviation - 7.2
t* = 0.8404 (Not significant compared to control)
'2-sample t test
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0.01% poloxalene resulted in a 24% increase in drug absorption over that 
of the control. Further increase in poloxalene concentration did not 
result in any further significant increase in the absorption of sulfis­
oxazole. The presence of 0.01 and 0.1% DOSS resulted in a 19-20% in­
crease in drug absorption. When the drug was administered in 1% DOSS, 
the increase was only 7%.
The absorption of sulfadiazine and the effect of poloxalene and 
DOSS is presented in Tables VIII through XII. The presence of 0.01 and 
0.1% poloxalene resulted in a 22% increase in the absorption of sulfad­
iazine. The increase in sulfadiazine absorption was 16.5% and 24% for 
0.01 and 0.1% DOSS respectively.
As discussed in an earlier section, surface active agents can 
improve drug absorption by increasing the solubility and dissolution 
rate of the drug in the gastrointestinal fluids, or by exerting a direct 
action on the membrane and thus enhancing the membrane permeability, or 
by altering gastric emptying, or by forming a more absorbable complex 
with the drug. The solubility data rule out complex formation and 
solubilizing effects of the surfactants used. The in situ intestinal 
loop preparation is not subject to gastric emptying effects. The in­
creased drug absorption therefore must be due to enhanced dissolution 
or membrane effects. In previous studies, poloxalene has been shown 
not to have a membrane effect. Therefore, the increased absorption of 
sulfisoxazole and sulfadiazine in the presence of all concentrations of 
this surfactant must be due to improved dissolution of the two drugs in 
the intestinal loop. The difference in the increase in drug absorption 
caused by different concentrations of poloxalene is not significant at
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TABLE VIII
Absorption of Sulfadiazine from Rat Intestinal 
Loops in the Absence of any Surfactants
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 10.1 5.9 58.9
2 10.0 5.6 55.8
3 10.0 5.1 51.0
4 10.0 5. 8 58.0
5 10.2 5.6 55.1
6 9.7 6.4 66.0
Mean - 57.47
Standard Deviation - 5.0
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TABLE IX
.Effect of 0.01% Poloxalene on the Absorption of
Sulfadiazine from Rat Intestinal Loops
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 10.7 7.3 68.2
2 10.6 8.3 77.6
3 10.4 7.1 68.3
4 9.8 6.5 67.0
5 9.4 7.1 75.3
6 10.2 7.3 70.8
Mean - 70.65
Standard Deviation - 3.67
t* = 5.0906 (Significantly different from control at p <.001)
*2-saraple t test
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TABLE X
Effect of 0.1% Poloxalene on the Absorption 
of Sulfadiazine from Rat Intestinal Loops
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 10.8 7.9 73.0
2 10.6 7.8 73.3
3 10.7 7.0 65.6
4 10.6 7.4 69.6
5 10.6 7.1 67.1
6 10.3 7.4 72.0
Mean - 70.10
Standard Deviation - 3.22
t* = 5.1993 (Significantly different from control at p <.001)
^2-sample t test
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TABLE XI
Effect of 0.01% DOSS on the Absorption of
Sulfadiazine from Rat Intestinal Loops
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
1 10,1 7.2 71.0
2 10.0 6.0 59. 7
3 10.0 6.9 68.5
4 8.7 6.6 76.0
5 9.8 5.9 59.5
Mean - 66.94
Standard Deviation - 7.2
t* = 2.5676 (Significantly different from control at p <.05)
*2-sample t test
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TABLE XII
Effect of 0.1% DOSS on the Absorption of 
Sulfadiazine from Rat Intestinal Loops
Rat No. mg Administered mg Absorbed
Percentage
Absorbed
I 11.0 7.9 71.7
2 11.0 7.9 72.5
3 11.0 7.3 66.6
4 10.9 7.4 67.9
5 10.9 8.5 78.1
6 11.0 7.7 70.7
Mean - 71.25
Standard Deviation - 4.1
t* = 5.2448 (Significantly different from control at p <.001)
*2-sample t test
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at any reasonable probability levels. It is therefore suspected that a 
minimum concentration of poloxalene which is enough to cause better wet­
ting of the drug particles will do an equally good job of improving drug 
absorption as any higher concentration will do.
In the case of DOSS, drug absorption might be affected by two 
mechanisms. One, the dissolution effect due to improved wetting of the 
drug; and, two, a membrane effect. This surface active agent has been 
shown to have a membrane effect. In the presence of low concentration 
(below CMC) of DOSS, both mechanisms, better wetting and increased mem­
brane permeability, aid in. improving drug absorption. But at higher 
concentrations, though both of these mechanisms are still in operation, 
a third factor comes into play. The drug is entrapped in surfactant 
micelles and since micelie-entrapped drug is not available for absorp­
tion, the rate of absorption of the drug is reduced. This is what is 
suspected to have happened to account for the reduced absorption of 
sulfisoxazole in the presence of 1% DOSS.
The extent of increase in the absorption of both sulfisoxazole 
and sulfadiazine does not correlate quantitatively with the increase in 
their in vitro dissolution rates caused by the presence of either of 
the surfactants. The in situ intestinal loop preparation utilized in 
this study does not rule out the presence of residual mucin and bile.
Both of these physiological materials are known to be highly surface 
active. Their presence in the intestinal loop will tend to mask or 
minimize the surface active properties of surfactants administered along 
with the drug. However, since these physiological materials are common 
to all the animals used in the study, i.e., control as well as surfactant
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groups, the increase in drug absorption brought about in the presence 
of DOSS and poloxalene is due to the effect of these agents.
Though a quantitative relationship between dissolution and ab­
sorption is not evident, a qualitative one is nevertheless present. A 
significant increase in the dissolution (over the control) is observed 
in the presence of 0.001% of the surfactants. Increasing the concentra­
tion further does not result in further significant increase in drug 
dissolution. In absorption studies too, the lowest concentration of the 
surfactants causes a significant increase in drug absorption which is 
not improved by higher concentrations.
The extent of improvement in the dissolution and absorption of 
the drugs studied is the same for both poloxalene and DOSS. The latter 
has been shown in prior studies to have a direct effect on the perme­
ability of membranes. Based on these data, it is postulated that polox­
alene is a better choice over DOSS for incorporation in the suspension 
dosage form of poorly soluble drugs.
Absorption of Sulfisoxazole from Intact Rats. The effect of various 
concentrations of poloxalene and DOSS on the 24 hour urinary excretion 
of sulfisoxazole is presented in Tables XIII and XVIII. Neither of the 
surfactants had any significant effect on the amount of drug absorbed 
in 24 hours. These results coupled with the intestinal loop studies 
indicate that the surfactants studied increase the rate of drug absorp­
tion but do not alter the total amount absorbed. Studies in man also 
indicated a difference in rate but not in the extent of urinary excre­
tion of sulfisoxazole (73, 7).
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TABLE XIII
Effect of 0.01% Poloxalene on the 24-hr. 
Urinary Excretion of Sulfisoxazole
Rat
No. mg
Administered
Control
mg
Excreted
%
Absorbed
mg
Administered
Surfactant
mg % 
Excreted Absorbed
1 8.64 6.53 75-6 9.28 7.24 78.0
2 9.17 7.11 77.5 9.09 7.6 83.6
3 9.09 6.8 74.8 9.61 8.68 90 3
4 8.44 6.12 72.5 9.37 7.09 75.7
5 9.19 6.95 75.6 9.59 7.44 77.6
6 9.17 7.69 83.9 9.31 6.94 74.5
Mean - 76.65 
Standard Deviation - 3.9
Mean - 79.95 
Standard Deviation - 6.0
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TABLE XIV
Effect of 0.1% Poloxalene on the 24-hr. 
Urinary Excretion of Sulfisoxazole
Rat
No. mg
Administered
Control
mg
Excreted
%
Absorbed
Surfactant
mg mg 
Administered Excreted
%
Absorbed
1 9.49 7.36 77.6 9.92 7.44 75.0
2 8.93 6.78 75.9 9.87 8.43 85.4
3 8.74 6.13 70.1 9.87 8.60 87.1
4 9.41 7.36 78.2 9.59 7.44 77.6
5 9.71 7.93 81.7 9.79 8.10 82.7
6 9.57 8.26 86.3 9.75 7.02 72.0
Mean - 78. 3 Mean - 79. 97
Standard Deviation - 5.5 Standard Deviation - 6.0
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
41
TABLE XV
Effect of 1.0% Poloxalene on the 24-hr. 
Urinary Excretion of Sulfisoxazole
Rat
No. mg
Administered
Control
mg
Excreted
%
Absorbed
Surfactant
mg mg 
Administered Excreted
%
Absorbed
1 9.25 6.61 71.5 9.94 8.26 83.1
2 9.46 8.6 90.9 9.96 8.1 81.3
3 9.73 8.6 88.4 9.96 8.6 86. 3
4 9.78 6.65 68.0 9.96 8.6 86.3
5 8.86 6.12 69.1 9.94 8.43 84.8
6 10.14 7.19 70.9 9.37 7.44 79.4
Mean - 76. 47 Mean - 83. 53
Standard Deviation - 10.3 Standard Deviation - 2.8
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Effect of 0.01% DOSS on the 24-hr. 
Urinary Excretion of Sulfisoxazole
42
Rat
No. mg
Administered
Control
mg
Excreted
%
Absorbed
Surfactant
mg mg 
Administered Excreted
%
Absorbed
I 8.74 6.12 70.0 9.69 7,85 81.0
2 8.45 5.36 63.4 9.53 7.89 82.8
3 9.05 6.61 73.0 9.46 7.98 84.4
4 8.78 6.32 72.0 8.99 6.26 69.6
5 8.92 7.83 87.8 9.25 6.61 71.5
6 9.0 7.34 81.6 9.06 5.27 58.2
Mean - 74. 63 Mean - 74. 58
Standard Deviation - 8.7 Standard Deviation - 10.1
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TABLE XVII
Effect of 0.1% DOSS on the 24-hr. 
Urinary Excretion of Sulfisoxazole
Rat
No.
Control
mg mg 
Administered Excreted
%
Absorbed
Surfactant
mg mg 
Administered Excreted
%
Absorbed
1 8.94 6.28 70.20 9.90 8.25 83.30
2 9.29 7.04 75.80 9.96 8.51 85.40
3 9.32 6.45 69.20 9.98 8.68 87.00
4 9.57 6.90 72.10 9.96 9.90 99.40
5 9.04 7.59 84.00 9.95 7.60 76.40
6 9.20 7.52 81.7 9.94 6.82 68.6
Mean - 75-5 Mean - 83. 35
Standard Deviation - 6.2 Standard Deviation - 10.4
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TABLE XVIII
Effect of 1.0% DOSS on the 24-hr. 
Urinary Excretion of Sulfisoxazole
44
Rat
No- mg
Administered
Control
mg
Excreted
%
Absorbed
Surfactant
mg mg 
Administered Excreted
%
Absorbed
I 9.52 8.5 89.3 9.96 8.51 85.4
2 9.18 7.52 81.9 9.97 8.47 85.0
3 9.42 7.93 84.2 9.96 7.83 78.6
4 9.74 8.43 86.6 9.91 9.34 94,2
5 9.67 8.02 82.9 9.99 7.77 77.8
6 9.33 6.98 74.8 10.0 9.01 90.1
Mean - 83. 28 Mean - 85. 18
Standard Deviation - 4.9 Standard Deviation - 6.4
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PART TWO 
CARDIAC GLYCOSIDES
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CHAPTER IV
INTRODUCTION
In the area of bioavailability, no other single drug probably 
ever received as much attention as has digoxin. In 1971, Lindenbaum 
et al, (68) reported marked differences in the serum levels of digoxin, 
when four different tablet preparations of digoxin were administered 
to healthy volunteers. This difference in serum levels was observed 
even from tablets from the same manufacturer. Though this study did 
not conclusively prove that the bioavailability of digoxin from various 
tablets was different, only that the rates of absorption were different, 
the study acted as a primer for more detailed work. Since then, numer­
ous reports have appeared, proving beyond any doubt, that the bioavail­
ability of digoxin from its tablet dosage forms is quite variable. In 
many studies, a correlation between the digoxin tablet dissolution rate, 
in vitro, and the total availability of the drug, in vivo, was found, 
indicating that the absorption of digoxin is dissolution rate-limited. 
Though digitoxin is also suspected to exhibit differences in bioavail­
ability from its solid dosage forms, this drug has not been investigated 
as thoroughly as digoxin.
The potential for variability in absorption increases greatly 
with incompletely absorbed drugs. For drugs like digitoxin and digoxin, 
which have a steep dose-response curve and narrow range between toxic
46
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and therapeutic dose, it is imperative that their absorption be uniform 
and not subject to great intersubject and intrasubject variations. 
Available information at this time indicates that the differences in 
bioavailability of digoxin and digitoxin from their solid oral dosage 
forms are due to their poor solubility and hence low rates of dissolu­
tion in the fluids of the gastrointestinal tract. Poor formulation of 
a dosage form magnifies these factors.
Since the absorption of these two cardiac glycosides is dissolu­
tion rate limited and since they are absorbed passively from the stomach 
and upper portions of the small intestine, it follows that if the drugs 
are not in solution in the fluids of these regions, they will not be 
absorbed into the systemic circulation. Manninen et al (72) found that 
propantheline increased serum levels of digoxin while metoclopramide 
decreased the serum levels of digoxin administered as tablets. Propan­
theline had no effect on the absorption of a solution of digoxin given 
orally. Since propantheline reduces and metoclopramide increases gas­
trointestinal motility, the authors concluded that the absorption of 
digoxin from tablets is affected by the rate at which the dosage form 
travels down the gastrointestinal tract. Medin and Nyberg (77) studied 
the dissolution characteristics of the tablets of digoxin used by 
Manninen et al (72) and found that they had a very low rate of dissolu­
tion. They concluded that slow dissolution from these tablets is a 
necessary condition for the observations reported by Manninen et al (72) 
If the tablets were rapidly dissolving ones, GI motility might have had 
no effect as was observed for the digoxin solution.
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It was the purpose of the present study to try and improve the 
dissolution of digitoxin and digoxin in order to assure more uniform 
absorption. One of the means of increasing dissolution rates is to 
reduce the drug particle size.
SURVEY OF LITERATURE
When a drug is administered orally in solid form as a tablet, 
capsule or suspension, its absorption is frequently found to be depen­
dent on how fast it goes into solution in the fluids of the GI tract. 
Absorption in this case is said to be dissolution-rate limited and any 
factor that influences the dissolution rate will influence the absorp­
tion. As pointed out by Gibaldi (38), if a drug is more rapidly and/or 
more completely absorbed from solution than from a solid form, its 
absorption is quite likely dissolution rate limited.
Noyes and Whitney (82) were the first to describe dissolution 
quantitatively:
dA/dt = KS (Cg-C) (1)
where dA/dt is the amount of drug dissolved per unit time, K is the 
intrinsic dissolution rate constant and is equal to D/h, where D is the 
diffusion coefficient of the drug and h is the thickness of the diffu­
sion layer, S is the surface area of the dissolving drug, Cg is the 
concentration of the drug at the drug-solvent interface (which is essen­
tially equal to the solubility of the drug in the solvent) and C is the 
concentration of drug in the bulk of the solvent at time t. In dissolu­
tion rate limited absorption, C is negligible compared to Cg and there­
fore equation 1 can be written as :
dA/dt = DSCg/h (2)
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The diffusion coefficient D and the solubility Cs usually in­
crease with temperature, thus making dissolution rate temperature de­
pendent. D is inversely proportional to the viscosity of the medium 
and therefore an increase in viscosity leads to a decrease in the rate 
of dissolution. The thickness of the diffusion layer h, depends on the 
agitation intensity of the solvent around the dissolving particle. The 
greater the agitation, the thinner the layer and greater the dissolution 
rate. Any factor that affects the solubility Cs, influences the disso­
lution rate proportionately. In this study we were concerned with in­
creasing the surface area. This can be brought about by decreasing 
the particle size of the drug. Particle size effects are particularly 
important when dealing with slowly dissolving, poorly soluble materials.
A reduction of particle size results in more rapid dissolution and ab­
sorption of a drug. And in cases where dissolution rate is so low 
that incomplete absorption occurs, a reduction in particle size results 
in more complete absorption. It should be pointed out that the equa­
tions presented are for solids which maintain a constant surface through­
out the dissolution process. Slightly more involved equations are 
needed to represent accurately the dissolution process of multiparticu­
late systems and for particles whose surface area changes as the disso­
lution proceeds.
There are many ways of achieving a reduction in particle size, 
ranging from simple grinding in a mortar to the use of modern techniques 
like ultrasonic waves (97, 50, 102). Perhaps the most commonly used 
method of presenting fine particles to the gastrointestinal fluids is 
the use of micronized or microcrystalline particles. In addition to
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these methods, where particle size is reduced outside the biological 
system, there are ways of obtaining very fine particles within the gas­
trointestinal tract. If a drug is administered as a solution in a 
water-miscible organic solvent or if a water soluble salt of a weak acid 
is administered as an aqueous solution, the subsequent dilution with the 
acidic fluids of the stomach causes the drug to be precipitated in fine 
form (59).
Water-soluble salts of many poorly soluble drugs have been used 
as solid dosage forms. However, there are some drawbacks to their usage. 
It was shown that the soluble sodium salt of novobiocin had slower dis­
solution rate and gave lower plasma levels of novobiocin compared to 
the less soluble amorphous form of novobiocin (81). This is because the 
sodium salt had reacted with the atmospheric carbon dioxide and water to 
precipitate out the poorly soluble parent compound. Also, the alkalinity 
of some salts may lead to gastric distress.
SOLID DISPERSIONS
The reduction of particle size does not always result in in­
creased dissolution and absorption. This is because of the aggregation 
of the fine particles due to increased surface energy and the subsequent 
stronger Vander Waal's forces of attraction. Lin et al (67) showed that 
micronized particles of griseofulvin and glutethimide had a slower dis­
solution rate compared to coarser particles. Photomicrographs taken 
after 2 hours of dissolution showed that the particulate agglomerates 
of the micronized samples were larger in size than the coarser particles. 
The electrostatic charge of the powders was seen to increase with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
51
decrease in particle size. Moreover, fine powders are not easily wetted 
in water and wetting is the first step towards their dissolution (58).
Definition. The terra "solid dispersion", as pointed out by Chiou and 
Riegelman (26) refers to "the dispersion of one or more active ingred­
ients in an inert carrier or matrix at solid state prepared by the melt­
ing (fusion), solvent, or melting-solvent method". When the solvent 
method is used, the terra "coprecipitate" has also been used. To achieve 
fast release of a drug from a carrier it is generally necessary that the 
latter be highly soluble (there are exceptions, viz., nitrofurantoin- 
deoxycholic acid coprecipitate, reserpine deoxycholic acid coprecipitate) 
and that the drug be a minor component on the molar basis.
Sekiguchi and Obi (94) in 1961, introduced a unique approach of 
reducing particle size, that of solid dispersions. It consists of dis­
persing a poorly soluble drug by fusion or solvent methods in a highly 
water soluble, pharmacologically inert carrier. When this system comes 
in contact with the GI fluids, the carrier immediately dissolves, re­
leasing the drug in the form of very fine particles or even in molecular 
form. Because of the increased surface area of the drug, it dissolves 
rapidly. Levy (59) and Kanig (53) indicated the possibility of using a 
solid solution approach in which the drug is molecularly dispersed in a 
soluble carrier.
Sekiguchi et al (94) showed that solid dispersions of chloram­
phenicol in urea, at a weight fraction of 20:100 had a faster rate of 
dissolution and absorption. They attributed this effect to particle 
size reduction. Goldberg et al (41, 44) after examining the phase dia­
grams presented by Sekiguchi et al (94) purposed that the binary system 
of chloramphenicol-urea should be classified as a partial solid solution
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
52
and not as a simple eutectic mixture. Chiou (18) reexamined the same 
data and after further study proposed that the "original suggestion of 
Sekiguchi et al (94) of a particle-size effect in increasing dissolution 
and absorption of chloramphenicol is more in accord with the physical- 
chemical facts discussed here". Goldberg et al (41, 42, 43, 44) in a 
series of reports during 1965-1966 discussed the advantages of solid 
solutions over the eutectic mixture. Chiou and Riegelman (26) reviewed 
the literature on solid dispersions. Tachibana and Nakamura (110) used 
the solvent method to prepare a coprecipitate of 3-carotene and water- 
soluble polymers like polyvinylpyrrolidone. The dissolution rate of 
griseofulvin was markedly enhanced by dispersing it in polyvinylpyrroli­
done by the solvent method (75). The mechanism of increased dissolution 
rate of sulfathiazole dispersed in polyvinylpyrrolidone was discussed 
by Simonelli et al (100). Chiou and Riegelman (22) studied the disso­
lution characteristics of griseofulvin dispersed in polyethylene glycol 
of different molecular weights, in pentaerythritol, pentaerythrityl 
tetra acetate, and citric acid by the fusion method. Of these systems, 
the citric acid glass solution has the fastest dissolution rate for 
griseofulvin. The same authors (23, 24) showed that griseofulvin dis­
persed in polyethylene glycol 6000 was rapidly and almost completely 
absorbed in dogs and man, whereas the commercial micronized griseofulvin 
was only 30-60% absorbed. Svoboda et al (109), in a preliminary study, 
found polyvinylpyrrolidone coprecipitated acronycine to be more active 
than acronycine itself towards two tumors.
Chiou and Riegelman (25) reported that solid dispersions of 
digitoxin and some steroids in polyethylene glycol prepared by the 
fusion technique had significantly higher rates of dissolution. Stupak
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and Bates (106) found that with a 1:5 reserpine-polyvinylpyrrolidone co­
precipitate both the rate and extent of absorption of reserpine in the 
rat were significantly higher than that following either pure reserpine 
or a 1:5 reserpine:polyvinylpyrrolidone physical mixture. The in vitro 
dissolution characteristics of the three test preparations correlated 
very well with the in vivo absorption data. Dissolution rates of drugs 
solid-dispersed in polyethylene glycol 4000 were studied by Reiss (89). 
Drugs that were not soluble in polyethylene glycol 4000 did not show an 
increased dissolution rate while those that were soluble showed an in­
crease. Stoll et al (105) studied the dissolution and absorption of 
nitrofurantoin dispersed in deoxycholic acid by the solvent method.
They found that the dissolution rate of the dispersed system was six 
times greater than the pure drug at pH 7.4. At pH 1.2, the initial dis­
solution rate of the coprecipitate was higher than that of the pure drug 
but became slower after 35 minutes. The rate and extent of unchanged 
drug excreted in the urine was significantly greater when the copreci­
pitate was given to humans than when the pure drug was administered. 
Stupak and Bates (107) studied the dissolution and toxicity (in rats) 
of digitoxin in pure form as well as a 1:9 (w/w) coprecipitate in poly­
vinylpyrrolidone. They reported that about 11 times as much pure drug 
would have to be administered to reach the same amount of drug in the 
body as that attained following the administration of the drug as a 
coprecipitate. A correlation between the in vitro dissolution rates and 
in vivo toxicities of the test systems was found.
Partial solid solutions of corticosteroids in mannitol and glass 
(so called because of appearance) dispersions in dextrose, galactose and
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sucrose were prepared by Allen (5). The solid dispersions had a markedly 
higher dissolution rate compared to plain corticosteroid powder. The 
dissolution and absorption rates of a eutectic mixture of phénobarbital 
in urea were reported to be higher than those of pure phénobarbital (1).
Solid dispersions of primidone in citric acid ranging from 1-30% 
w/w were made by the fusion process and examined by x-ray diffraction 
and differential scanning calorimetry. Glasses containing 1-3% w/w of 
primidone could not be classified from the x-ray data but melting point 
data suggested the drug could be molecularly dispersed. Samples con­
taining 5-15% of the drug were simple eutectic mixtures and in the 30% 
glass, primidone was present in the amorphous form. It was noted that 
the primidone recrystallizing from the glass solution was a different 
polymorphic form than the one used to prepare the solid dispersion (108).
Methods of Preparation of Solid Dispersions
Melting Method. The melting or fusion method of preparing solid dis­
persions was first proposed by Sekiguchi et al (94). The physical 
mixture of drug and carrier was heated until both components melted and 
the melt was then cooled and solidified rapidly, under vigorous stir­
ring in an ice bath. Some modifications of this technique were to pour 
the melt onto ferrite or steel plates and cooling by flowing air or 
water on the other side of the plates. Systems of griseofulvin-citric 
acid were found to harden more rapidly at 37* C rather than at room 
temperature (22). The advantage of the direct melting method is its 
simplicity and economy. Also, because of the sudden quenching of the 
melt, a finer dispersion of the drug in the matrix results. This
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technique can, however, be applied only to those materials which are 
stable at high temperatures. Melting under vacuum or a blanket of nit­
rogen to prevent oxidation has been employed (87). Chiou found some de­
composition of digitoxin when he employed the fusion method. Since the 
melting point of a binary system depends on its composition, some com­
binations might have a melting point lower than those of either of their 
ingredients. In such cases the fusion techniques might be applicable 
even though the conponents might decompose near their individual melting 
point.
Solvent Method: This method involves the dissolving of the two ingred­
ients, drug and carrier, in a common solvent and evaporating the solvent 
in vacuo. The advantage of this method is that there is no chance of 
decomposition of the drug. The drawbacks are many— long time required 
to evaporate the solvent, cost of the solvents, the difficulty in com­
pletely removing the solvent and the possible adverse effect of the 
traces of solvent on the chemical stability of the drug. Also, a super- 
saturation of the drug cannot be obtained except in highly viscous 
systems.
Melting-Solvent Method. A method which possesses the advantages of both 
the solvent and the fusion methods is the melting-solvent method. The 
drug is dissolved in a minimal amount of solvent and the resulting solu­
tion incorporated into the melt of a water soluble matrix or carrier. 
However, this technique can be used only for drugs with a very low thera­
peutic dose.
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Classification of Solid Dispersions
Chiou and Riegelman (26) classified solid dispersions into six 
main groups: (1) Simple eutectic mixtures, (2) solid solutions, (3)
glass solutions and glass suspensions, (4) amorphous precipitation, (5) 
compound or complex formations between drug and carrier, and, (6) any 
combinations of (1) through (5).
Simple Eutectic Mixtures. A simple eutectic mixture results when a melt 
of two substances which, show negligible solid-solid solubility and com­
plete liquid miscibility, is rapidly solidified. From a thermodynamic 
point of view such a system is regarded as an intimate physical mix of 
its two crystalline components.
Based on the assumption that the two components are present in 
very small crystals, when a eutectic mixture (composition E in Figure 1) 
is exposed to the dissolution fluids, the carrier goes into solution 
immediately, exposing the drug, which because of its large surface area 
also dissolves rapidly (94). In addition to the reduced crystal size, 
the following factors might also be playing a role in the increased rate 
of dissolution:
LIQUID SOLUTIOlI— J
SOLID B 
+ LIQUID
SOLID A + LIQUID
SOLID A /|ND SOLID B
A (100%) B(100%)E
Figure 5--Phase diagram of a simple eutectic mixture with 
negligible solid solubility. (From ref. 26).
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(a) If most of the drug crystallites are extremely small its 
solubility would be higher.
(b) As the carrier dissolves, a saturated solution of it sur­
rounds the drug particles, and a possible solubilizing effect on the 
drug might be operative. This was demonstrated by the faster dissolu­
tion rate of acetaminophen from its physical mixture with urea. The
fact that the solubility of acetaminophen in water was higher in the pre­
sence of urea lends further support to the hypothesis of a solubilizing 
effect in the microenvironment of the drug particles (44). Bates (8) 
also suggested a similar mechanism for the increased dissolution rate of
reserpine from a physical mixture with polyvinylpyrrolidone.
(c) When very fine particles of a poorly soluble drug are put 
in an aqueous media, the particles tend to form aggregates and agglom­
erates. This problem is not encountered with solid dispersions because 
they are separated by the water soluble carrier. As the carrier dis­
solves, the drug particles become surrounded by the aqueous media which 
results in better wetting.
(d) An increased rate of dissolution and absorption would also 
occur if the drug crystallizes in a metastable form from the fused mix­
ture. Since a metastable crystalline form has higher solubility, this 
would result in an improved dissolution. If the drug does in fact 
crystallize in a metastable form, it is possible that after a length of 
time, the dissolution rate of the eutectic would not be the same as 
when it was freshly prepared.
The composition of the eutectic determines to some extent the 
particle size of the crystallite. If it is made up of a small weight 
fraction of the drug, a finer crystallization can be obtained.
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Solid Solutions. A solid solution, as the name implies, consists of a 
solid solute dissolved in a solid solvent. It was suggested (41) that 
a solid solution of a poorly soluble drug in a rapidly soluble matrix 
has a faster dissolution rate compared to a eutectic mixture because 
the drug is present in its smallest state of subdivision, the molecular 
state, in a solid solution. In addition to this extremely fine particle 
size obtained in a solid solution, the factors (a-c) discussed under 
Simple Eutectic Mixtures might also be responsible for a high rate of 
dissolution from a solid solution. As pointed out by Chiou and Riegelman 
(26), "the advantage of a solid solution may not be so significant if it 
is exposed to a medium with a volume much less capable to dissolve all 
the drug". If this is done, the drug might precipitate unless it is 
being absorbed or removed in some other way.
Based on the crystalline structure, solid solutions can be div­
ided into substitutional or interstitial solid solutions. In the sub­
stitutional type, a molecule of the solute replaces a molecule of the 
solvent in the crystal lattice of the solid solvent. To achieve an ex­
tensive solid solution of this type, the size of the solute and solvent 
molecule should be very close to each other.
In interstitial solid solutions, a solute molecule resides in 
the interstitial space of the solvent crystal lattice. It is obvious 
that the size of the solute is critical in achieving such a solid solu­
tion.
Glass Solutions and Glass Suspensions. "A glass solution is a homogen­
eous, glassy system in which a solute dissolves in a glassy solvent."
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Glass suspension is a mixture in which precipitated particles are sus­
pended in a glassy solvent. The term glass is used here to mean the 
transparency and brittleness of the material. Since a glass solution is 
closer in similarity to a liquid solution than a solid solution, its 
lattice energy is expected to be much lower. The dissolution rate of 
drugs in glassy solutions was therefore expected to be much faster than 
that in a solid solution. It was also pointed out (26) that when the 
solute content exceeds the solubility, the particle size of crystalli­
zation of the solute is much smaller in a glass solution than in a 
solid solution. This was said to be due to the difficult crystal growth 
in the viscous medium. Griseofulvin showed a marked increase in disso­
lution rate in a citric acid glass solution (22).
Amorphous Precipitations in a Crystalline Carrier. In these systems the 
drug is present in an amorphous form in a crystalline carrier. Since 
the amorphous form of a drug is its highest energy form, it should, 
theoretically, dissolve much more rapidly than a crystalline form. It 
was suggested by Chiou and Niazi (20) that the increased oral absorp­
tion of sulfathiazole from the sulfathiazole-urea systems (94) was 
mainly due to the presence of the drug in an amorphous form.
Compound or Complex Formation. Scheme 1 (26) represents the dissolution 
and absorption of a drug from a complex or compound.
dissolution Kj
Dn Cm ---------- *■ Dn Cm v-ÿ - - + mC
(solid) (solution)  ̂ (solution)
I absorption | absorption
blood stream or circulation
Where D = drug
C - soluble carrier
Scheme I
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It is seen that the availability of a drug depends on the solu­
bility, the dissociation constant, and the intrinsic absorption rate of 
the complex. Though the water-soluble polymers may be suitable for use 
as carriers in making solid dispersions of many drugs, the possibility 
of complex formation must be given due attention. The pharmacological 
action of penicillin, novocaine, prostigmine, hexobarbital, quinine (85) 
and hexylresorcinol (37) was retarded by polyvinylpyrrolidone. The re­
duced rates of dissolution and permeation of phénobarbital through 
everted rat guts was shown to be due to complex formation between the 
drug and polyethylene glycol 4000 or 6000 (101). Though the fact that 
the solubility of griseofulvin in 7% aqueous polyethylene glycol 6000 
is doubled indicates complexation, such a water-soluble complex did not 
retard the oral absorption of the drug in man and dogs (24, 23). The 
formation of a soluble complex with a low association constant can in­
crease dissolution and absorption of a poorly soluble drug. The forma­
tion of complex in the melt state does not necessarily mean it will 
occur in a liquid medium too; the reverse is also true. Although suc­
cinic acid increased the solubility of griseofulvin in water, their 
interaction could not be detected in the phase diagrams (19).
Combinations and Miscellaneous Mechanisms. Sometimes a combination of 
any of the five groups discussed might contribute to the formation of a 
solid dispersion and, therefore, the increased dissolution and absorp­
tion of such a system is due to the combined influence of different 
mechanisms. Thus, if griseofulvin is dispersed in high concentrations 
in polyethylene glycol, it may exist in both molecular state as well as
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microcrystalline particles. The coprecipitates^of reserpine with various 
bile acids such as deoxycholic acid (71), cholic, lithocholic, and tri­
hydroxy cholane (28) had greater blepharoptotic activity in mice com­
pared to the pure drug. This effect was postulated to be due to factors 
like decreased particle size, better wetting, reduced surface tension, 
etc.
Methods of Determining Types of Solid Dispersions
A single method rarely provides complete information about the 
physical nature of a solid dispersion and therefore a combination of two 
or more methods is needed for its complete elucidation.
Thermal Analysis. Several techniques based on the principle of change 
of thermal energy with temperature, constitute the most common means of 
studying the physicochemical interaction of two or more components.
(a) Cooling-curve Method: Physical mixtures of various compositions 
are heated until a homogeneous melt results and the temperature is then 
recorded as a function of time. From a series of such temperature-time 
curves, a phase diagram is constructed. A large amount of sample is 
needed, and only those samples which are stable when melted can be used. 
Moreover, it is time consuming; and, if cooling is rapid, slope changes 
might be missed. Small solid-solid solubility cannot be detected. 
Guillory et al (47) used this method to construct phase diagrams of 
deoxycholic acid-menadione and caffeine-phenobarbital.
(b) Thaw-melt Method: Thaw point is the temperature at which a solid
just begins to melt. A mixture of the components is prepared by the
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solvent method or the fusion method and then the thaw point is observed 
by gradually heating it in a capillary tube. A stirring device in the 
capillary was used (96) to achieve more accurate results. The stirring, 
while achieving uniform systems, affects the melting point but not the 
thaw point. The thaw point can be used to differentiate between a simple 
eutectic mixture from a limited solid solution. Since this method de­
pends on subjective observations, results are not quite reproducible.
The thaw point had a range of six degrees for a chloramphenicol-urea 
system (95).
(c) Thermomicroscopie Method: A physical mixture of the components
on a glass slide covered with a cover slip is heated until it melts 
completely. It is cooled and then heated at a slow, steady rate and the 
thaw and melting points are observed using a hot-stage polarizing micro­
scope. The method is simple and needs small quantities of the sample 
but can be used for thermally stable mixtures only and being subjective 
may not give reproducible results. Chiou and Niazi (21) using differential 
thermal analysis and x-ray diffraction, disproved the existence of a 
partial solid solution of griseofulvin in succinic acid, which was re­
ported by Goldberg et al (43) who used the thermomicroscopic method to 
reach their conclusions.
(d) Differential Thermal Analysis (DTA): This is a highly repro­
ducible method of constructing phase diagrams. It consists of record­
ing the differential effects caused by physical and chemical changes 
when a material is heated at a steady rate. Polymorphic transformations, 
evaporation, sublimation, and other types of decomposition can be
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detected, in addition to thawing and melting points. Small amounts of 
eutectic can be very easily detected by this method.
X-Ray Diffraction Method. It consists of measuring the intensity of 
x-rays as a function of diffraction angles by the sample. DTA and x-ray 
diffraction methods, in combination, seem to give the most information 
any two methods can give about the physicochemical interactions in a 
solid dispersion system. The combination has been put to extensive use 
in studying sulfathiazole-urea (20), chloramphenicol-urea (18), 
griseofulvin-succinic acid (21) systems.
A diffraction spectrum which shows the diffraction peaks of each 
crystalline component, indicates a simple eutectic mixture. The lattice 
parameter of the solvent crystal, in a solid solution of the substitu­
tional type, may be either increased, decreased or unchanged, depending 
on the relative size of the solute atom or molecule (103). In a contin­
uous solid solution, there is a shift of the diffraction lines from the 
position in one pure component to those in the other (17). A gradual 
shift in the positions with changes in composition quite often indicates 
that a solid solution exists. This gradual shift is due to changes in 
the lattice parameter. In a diffraction spectrum of a solid solution of 
the interstitial type, the peaks due to the solvent, i.e., the carrier, 
may or may not be changed, but those due to the solute will disappear.
The x-ray diffraction technique has also been employed to quanti­
tate the concentration of a crystalline component in a mixture (17, 2, 
57). It is obvious that if the concentration of the crystalline compon­
ent is extremely low, or if the diffraction intensity of this component
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is very weak, it is not possible to quantify its concentration. A broad­
ening and an increase in the height of the diffraction peaks might indi­
cate crystallite size reduction, usually below 0.2 p. Simonelli et al 
(100) attributed the loss of sulfathiazole diffraction peaks to the ex­
tremely fine crystalline dispersion of the drug in polyvinylpyrrolidone.
In addition to detecting simple eutectic mixtures and solid solu­
tions, the x-ray method can also help in detecting compound or complex 
formation. The spectra of a complex are quite different from the spectra 
of its components. If the solute is present in an amorphous form or if 
it exists as a molecular dispersion, the diffraction peaks of the solute 
disappear. In such a case, the x-ray diffraction spectra cannot be 
utilized to differentiate one from the other unless there is a change in 
the lattice parameter of the solvent. This is encountered especially in 
the cases where a drug is present in low concentrations in a solid dis­
persion system.
Microscopic Method. This has been used to study the morphology (95) and 
polymorphism (48) of solid dispersed systems.
Spectroscopic Method. B-carotene, dispersed in low concentration in 
polyvinylpyrrolidone, was examined by the visible absorption spectro­
scopic method (110). The spectrum of the B-carotene dispersed in poly­
vinylpyrrolidone resembled that of 3-carotene dissolved in organic sol­
vents but not that of 3-carotene particles. This indicates that 3- 
carotene is molecularly dispersed in the carrier. No marked interaction 
between 3-carotene and the carrier was suspected because the I R bands 
of the dispersed 3-carotene showed no detectable shift.
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Dissolution Rate Method. Allen and Kwan (4) proposed this method to 
evaluate the degree of crystallinity in solid-solid equilibria. The 
molecular dispersion (i.e., glass or solid solution) and a physical mix­
ture of the same chemical composition are compressed into constant- 
surface tablets and the in vitro dissolution rates of the solute compon­
ent are compared. Though the simplicity of the method makes it attrac­
tive, it can be applied only to those systems where a constant surface 
can be maintained throughout the period of study. To apply this method, 
it is mandatory that (1) the dissolution rate be proportional to the 
surface area of the tablet, (2) the difference between the dissolution 
rates of the physical mixture and the dispersed system be large, and 
(3) the drug present in both the systems be the same polymorphic form.
In addition, the assumption that the particle size of the drug released 
from the solid or glass solution does not affect the dissolution rate 
is made. This assumption is still to be proved.
Aging of Solid Dispersions
Either because of coarsening of dispersed phase particles or 
because of change of a metastable form to a more stable form, both of 
which are possible due to aging, the increased dissolution and absorp­
tion of a freshly prepared solid dispersion may not be seen after a 
length of time. The drug literature does not contain many reports 
dealing with this topic. Different polymorphic forms in the solid dis­
persion might have different chemical stabilities (48). Chiou and Niazi 
(20) found that the DTA thermograms and the x-ray diffraction spectra 
of solid dispersions of sulfathiazole in urea showed changes after aging.
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They noticed that the diffraction spectrum of freshly prepared 52% sul­
fathiazole solid dispersion had no peaks due to sulfathiazole but the 
same sample after being kept at 27° for 2 weeks showed some diffraction 
peaks of sulfathiazole Form II. It was found that this appearance of 
Form II was temperature dependent.
Review of In Vivo Studies
Sulfathiazole-Urea Systems. Sekiguchi and Obi (94) showed that the ab­
sorption of sulfathiazole was both faster and higher when the drug was 
administered as an eutectic mixture than the 50-100 mesh particles of 
the pure drug. In comparing the physical mixture of sulfathiazole and 
urea with plain sulfathiazole, no differences in the drug absorption 
were noted. The solubility of the drug in the presence of urea was seen 
to be decreased. On the basis of these results the authors concluded 
that urea does not enhance the absorption of sulfathiazole due to any 
physiological or physicochemical factors and that the increased absorp­
tion of the drug from a eutectic mixture is because of the presence of 
the drug in a microcrystalline state.
Chloramphenicol-Urea Systems. In studies with rabbits (95), a suspen­
sion of a 20% chloramphenicol-80% urea solid dispersion produced a 
higher and faster absorption in the first hour than the pure chloram­
phenicol. The total area under the blood level-time curves was the same 
for both dosage forms. When capsules were administered, the solid dis­
persion gave a more dramatic increase in drug absorption over the first 
four-hour period. The solid dispersion of 76% chloramphenicol-24% urea, 
the eutectic composition, given in both capsule and suspension form, had
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lower absorption than the pure drug. As was pointed out earlier, when 
a solute is present in lower concentrations, a finer particle-size dis­
persion is obtained. This might have been the reason for the difference 
in absorption between solid dispersions of the two compositions studied.
Reserpine-Bile Acid Coprecipitates. The blepharoptotic activity of re- 
serpine when administered as a coprecipitate with deoxycholic acid to 
mice was significantly enhanced and the onset of action was also con­
siderably reduced (71). This enhancement was generally increased as 
the concentration of the drug in the coprecipitate decreased, with the 
exception of the 1:32 molar ratio of reserpine to deoxycholic acid, 
which was the lowest concentration dispersion studied. A rank correla­
tion with the in vitro dissolution rate was found (39). Since deoxy­
cholic acid is not a normal bile acid for mice, Decato et al (28) then 
made coprecipitates of reserpine with cholic acid (indigenous to mice) 
and other bile acids not present in mice (lithocholic acid, trihydroxy- 
cholane and cholanic acid) to study if the enhanced blepharoptotic 
activity of the deoxycholic acid coprecipitate was limited to this acid 
only. It was found also that coprecipitates with cholic and lithocholic 
acids had significantly increased blepharoptotic activity, trihydroxy- 
cholane system had only a slight increase in activity and cholanic acid 
system about the same activity as the reserpine base. Stoll et al (104) 
in order to elucidate the mechanism of increased blepharoptotic activity 
of these systems undertook the study of their surface tension and dis­
solution properties. A qualitative correlation between surface tension- 
lowering ability and increased blepharoptotic activity was noted. The
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rate of dissolution of reserpine from the coprecipitates in a 1:16 molar 
ratio showed a rank order correlation with in vivo potency.
Griseofulvin-Polyethylene Glycol Systems. A comparison of the avail­
ability of griseofulvin from solid dispersed systems and micronized com­
mercially available powders was carried out in dogs (23) and man (24). 
Total urinary excretion data for 48 hours showed that 88% of dispersed 
(10% w/w) griseofulvin, 45% micronized griseofulvin in capsule form and 
33% of micronized griseofulvin in tablet form were absorbed. A linear 
relationship between the amount absorbed and logarithm of the in vitro 
dissolution rates was found. The absorption of griseofulvin administer­
ed to man as 10 and 25% dispersions in polyethylene glycol 6000 was al­
most complete and the absorption was over within about two hours. Mic­
ronized griseofulvin was only 43% absorbed and continued for 30-80 hours.
Nitrofurantoin-Deoxycholic Acid Coprecipitates. The in vivo absorption 
of a 1:5 coprecipitate, a 1:5 physical mixture and pure nitrofurantoin 
was determined. The coprecipitate showed significant increases in both 
the initial urinary excretion rate and the cumulative excretion of nit­
rofurantoin over the other two systems. In pH 7.4 buffer, the dissolu­
tion rate of the coprecipitate system was six times greater than that of 
the physical mixture (105).
Digitoxin-Polyvinylpyrrolidone Coprecipitates. Oral toxicity experiments 
were carried out in rats to give an indication of the total availability 
of digitoxin when the drug was administered as a 10% w/w digitoxin- 
polyvinylpyrrolidone coprecipitate. The LDgQ of pure digitoxin was
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found to be 88 mg/kg, and the LDgg of the coprecipitate was 7.8 mg/kg. 
The animals which received toxic doses of the coprecipitate died much 
earlier than those receiving the pure drug (107).
OBJECTIVES OF RESEARCH
The rate of absorption of poorly-soluble drugs like digoxin and 
digitoxin is dissolution rate-limited. Slow dissolution results in in­
complete, erratic and unpredictable absorption. The inter-subject and 
intra-subject variation in the absorption of orally administered solid 
preparations of digoxin obtained from different manufacturers, and from 
different lots of the same manufacturer has been well documented in 
current literature. This variation in absorption in normal, healthy 
subjects has been repeatedly stressed to be due to the differences in 
the dissolution rates of the solid oral dosage forms and not due to any 
biological factors. Solid dosage forms of digitoxin are also suspected 
of exhibiting bioavailability differences. Increasing the dissolution 
rate of these drugs would perhaps minimize the variation in their oral 
absoiption.
One way of increasing dissolution rates of drugs is to decrease 
their particle size. A unique way of achieving this is through solid 
dispersions. The purpose of this study was:
1. To prepare coprecipitates of digoxin and digitoxin in two carriers, 
poloxalene and deoxycholic acid and to determine their dissolution 
characteristics in water,
2. To assess the relative toxicity of the digitoxin and digoxin copre­
cipitates in mice, as an indicator of oral absorption, and
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3. To examine the nature of solid dispersions obtained by use of the 
x-ray diffraction technique.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER V 
EXPERIMENTAL 
Materials
Digoxin, Lanoxin^, Lot No. 57177, Burroughs Wellcome Co,
Digitoxin, Lot No, W11097, Eli Lilly and Co.
Poloxalene, Pluronic F-68^, Wyandotte Chemicals.
Deoxycholic acid. Nutritional Biochemicals Corp.
Procedures
Preparation of Coprecipitates. The solvent method of preparing solid 
dispersions was employed. The drug and carrier, in amounts which would 
give 1 and 10% w/w of the drug in the coprecipitate system were dissolved 
in alcohol. The solvent was removed in a rotary evaporator, under vacuum 
and the system left under vacuum overnight. The next morning, the co­
precipitate was ground in a mortar and sieved. The fraction which passed 
through a number 80 sieve but did not pass through a 100 mesh sieve was 
collected and used for in vitro or in vivo studies. Precipitated digi­
toxin and digoxin were prepared by treating the drugs in a similar manner. 
Physical mixtures composed of 1 and 10% w/w of the drugs and deoxycholic 
acid were prepared by mixing the components on paper with a spatula.
In the case of poloxalene, which is flaky and does not permit 
powdering to make a physical mixture with the drugs, its solution was
71
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employed. This solution contained either 135 mg or 1485 mg of it in 
500 ml water, which correspond to the amounts present in its 10 and 1% 
coprecipitates respectively.
Determination of Dissolution Rates. The dissolution characteristics of 
Cl) digitoxin and digoxin in the form of 1 and 10% w/w coprecipitates 
in the two carriers, (2) pure digitoxin and digoxin, (3) precipitated 
digitoxin and digoxin, and, (4) physical mixtures of the drugs with the 
two carriers were determined. In all cases, the amount used contained 
15 mg of the drugs.
The beaker method of Levy (63) with slight modifications was 
used. The dissolution medium consisted of 500 ml of water maintained at 
37*, in a one-liter beaker immersed in a constant temperature water bath. 
Stirring was provided by a 3-blade, 1-3/4 inch diameter polyethylene 
stirrer (No. 6160, Nalge) rotating at a speed of 60 rpm and dipped in 
the water to a depth of 3.5 cm. Unless otherwise specified, a 80/100 
mesh powder was always used. The test system was added to the dissolu­
tion medium and 5 ml samples taken out every half hour for the next
three hours and filtered through a Millipore into a flask kept at 37° 
to prevent crystallization of the drug. Five milliliter fresh dissolu­
tion medium was added back to the beaker after each sampling. The
amount of drug in solution was determined by the slightly modified color­
imetric method of Mesnard and Devaux (79). Each dissolution rate exper­
iment was run in duplicate. A cumulative correction was made for the 
previously removed samples in determining the total amount dissolved at 
a particular time by using the formula:
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n— 1
-  C n , m e a s .  -5̂  • 5 Z Z
where Cn,meas. denotes the spectrophotometrically measured concentration, 
and Cn is the concentration of the nth sampling expected in the medium 
if the previous samples had not been removed.
The amount of carrier present did not interfere with the assay 
for the drugs.
Solubility Determinations. The solubility of digitoxin and digoxin in 
water at 37® was determined. Also, the effect of two concentrations of 
poloxalene and deoxycholic acid, those corresponding to the 1 and 10% 
coprecipitate systems, on the solubility of digitoxin and digoxin was 
determined.
Excess of the drugs (20 mg) were placed in Erlenmeyer flasks 
along with 20 ml of water or 20 ml of water and the carriers. The flasks 
were tightly stoppered and equilibrated at 37® in a Metabolyte water bath 
shaker. Equilibrium solubility was determined by repetitive sampling.
Assay Procedure. The colorimetric assay of Mesnard and Devaux (79) was 
used to analyse any and all solutions of digitoxin and digoxin. The 
presence of poloxalene or deoxycholic acid did not interfere with the 
assay.
To 3 ml of drug solution was added 0.5 ml of 0.01 N periodic 
acid in 0.1 N sulfuric acid. After allowing a 10 minute oxidation per­
iod, 1 ml of 2% sodium arsenite solution in 0.5 N hydrochloric acid was 
added to stop the oxidation. Four milliliter of the mixture was added 
to 4 ml of a 0.6% aqueous solution of thiobarbituric acid adjusted to
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pH 2, in a 10 ml volumetric flask. The flask was then heated in a boil­
ing water bath for 20 minutes after which it was cooled to room temper­
ature and the volume made up with distilled water. The absorbance was 
read at 530 nm against a blank treated similarly. A Beer's Law plot was 
constructed and was used for determining the drug concentrations in the 
dissolution studies, solubility studies and in analyzing the coprecipi­
tate systems for drug content.
Toxicity Studies in Mice. The absorption of a drug may be indirectly 
assessed by determining its oral toxicity. To accomplish this, the 
relative toxicities of pure digitoxin and digoxin were compared with 
that of the 10% physical mixtures and coprecipitates of the two drugs 
in the two carriers.
Protocol for in Vivo Studies. Male albino mice (Horton Labs., California), 
weighing 16-28 gm were deprived of food 16-18 hours prior to the drug ad­
ministration. Water was allowed ad libitum. The drug was administered 
by gastric intubation as a suspension in a 0.5% w/v methyl cellulose 
(100 cp) aqueous vehicle. The concentration of the suspension was ad­
justed such that the dose to be administered would be contained in a 
volume of 0.2 ml per 10 gm (for digitoxin) or 0.4 ml per 10 gm (for dig­
oxin) body weight. The animals were returned to cages after drug admin­
istration and food and water allowed ad libitum. The number of deaths in 
seven days after administration was noted.
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CHAPTER VI
RESULTS AND DISCUSSION
Digitoxin-Poloxalene Coprecipitates. The dissolution characteristics of 
digitoxin-poloxalene test preparations are illustrated in Fig. 6 and 
Table XIX. Digitoxin present in both 10 and 1% coprecipitates dissolves 
at a significantly higher rate than the pure drug. The 1% coprecipitate 
releases the drug much faster than the 10% coprecipitate. Several fac­
tors which could be contributing to this enhanced rate of dissolution 
were investigated. The factors considered were: (a) The formation of
digitoxin-alcohol solvate, (b) the formation of a digitoxin-poloxalene 
complex having greater solubility than the pure drug, and, (c) the form­
ation of an amorphous or polymorphic form of digitoxin due to coprecipi­
tation of the drug with the carrier.
Digitoxin is known to form solvates with alcohol which are 
stable in vacuo (78). Drug solvates have been known to have markedly 
different rates of dissolution compared to the pure drugs (99). There­
fore, the effect of treating (dissolving in alcohol and removing the 
solvent in vacuo) digitoxin on the letters dissolution rate was studied. 
As shown in Fig. 6, such a treatment causes digitoxin to dissolve at a 
slightly faster rate than the untreated drug. The small difference in 
the dissolution rates of the pure and treated drug does not account for 
the considerably faster dissolution of the drug from the coprecipitates.
75
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Figure 6.— Dissolution rates of digitoxin from poloxalene test
preparations. Key: 0  , treated d r u g ; V  , 10% physical 
mixture; □ ,  1% physical mixture; 10% coprecipitate; 
0 ,  1% coprecipitate; g  , untreated drug.
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TABLE XIX
Dissolution Rate Studies of Digitoxin 
Test Preparations in Water at 37®
Concentration of Digitoxin^ Cug/ml) 
in Solution from 
Test Systems
: (minutes) I II III IV V VI VII VIII IX X
30 1.20 0.48 10.44 3.06 20.21 3.60 7.32 1.32 13.39 1.01
60 1.45 0.89 10.95 3.50 20.41 4.13 10.99 1.77 15.39 1.47
90 1.62 1.13 11.18 3.76 20.24 4.39 13.98 1.87 16.72 1.59
120 1.71 1.36 11.23 3.85 18.95 4.53 16.13 1.94 16.57 1.69
150 1.93 1.26 11.53 3.86 19.88 4.60 17.41 2.02 18.72 1.81
180 2.15 1.35 11.45 3.95 20.07 4.69 19.81 2.13 19.08 1.98
I Treated drug.
II Untreated drug.
Ill 10% coprecipitate with poloxalene.
IV 10% physical mixture with poloxalene. 
V 1% coprecipitate with poloxalene. 
%1ean of two experiments
VI 1% physical mixture with poloxalene.
VII 10% coprecipitate with deoxycholic acid. 
VIII 10% physical mixture with deoxycholic acid. 
IX 1% coprecipitate with deoxycholic acid.
X 1% physical mixture with deoxycholic acid.
00
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The 1% coprecipitate dissolved significantly faster than the 10% 
coprecipitate. The former contains eleven times as much poloxalene as 
the latter. Complete dissolution of the carrier present in the 1% co­
precipitate yields a 0.297% solution which is about three times the CMC 
value of this surfactant. Surface active agents increase the dissolu­
tion rate of drugs either bacause of lowering of interfacial tension be­
tween the drug particle and the dissolution medium, which results in an 
increase in the effective surface area of the drug, or due to mi cellar 
solubilization. Therefore, the effect of two poloxalene concentrations, 
0.027% and 0.297%, corresponding to the 10 and 1% coprecipitates respec­
tively, on the dissolution of the drug was studied. Digitoxin was found 
to dissolve at a faster rate in the presence of both the surfactant con­
centrations than in plain water.
Equilibrium solubility in the above surfactant solutions (0.027% 
and 0.297%), at 37®, was determined. No difference was observed between 
the solubility of digitoxin in water (0.62 mg/100 ml) and in the surfac­
tant solutions. When the solubility of a drug is increased by a surfac­
tant, an interaction of the two entities is suspected. The results of 
equilibrium solubility studies indicate lack of drug-carrier interaction. 
The slightly faster dissolution of the drug in the more concentrated 
poloxalene solution (Fig. 6) might be due to better wetting of the drug.
Since the above mentioned facts indicate that the enhanced dis­
solution of digitoxin from the coprecipitates cannot be fully accounted 
for as due to solvate formation, surface tension-lowering by the carrier, 
or due to drug-carrier complexation, other factors must be considered.
The enhanced dissolution of digitoxin from the coprecipitates and the
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difference between the rate of solution of the 10 and 1% coprecipitates 
seems to be a particle size-effect (1053. During the preparation of the 
coprecipitate, initially both the drug and the carrier are in solution. 
As the solvent gets evaporated, a supersaturated solution results. This 
is apparent because all the material still remains in solution although 
the quantity of solvent is reduced to a much smaller volume than that
required to get the drug and carrier to dissolve initially. The super­
saturated solution finally loses enough solvent and a rapid precipita­
tion of the two components occurs. The short time interval for the
complete removal of the solvent causes the drug to precipitate in ex­
tremely fine form. Because the ratio of drug to carrier is much smaller 
in the 1% coprecipitate, crystallization of the drug might be hindered 
more and much finer crystals might result compared to the 10% system.
Preliminary In vivo absorption studies were undertaken to find 
if the In vitro dissolution enhancements of digitoxin from its copreci­
pitates cause a similar increase in the absorption of the drug from the 
GI tract. Drug absorption may be assessed indirectly by determining its 
oral toxicity (107). This method is based on the fact that the toxicity 
of an orally administered drug is directly proportional to the logarithm 
of the amount of drug in the body which in turn is directly proportional 
to its rate of absorption from the GI tract. Oral drug absorption was 
assessed by determining the number of deaths in mice given the same dose 
of digitoxin as pure drug, as 10% w/w drug-carrier physical mixture and 
as 10% w/w drug-carrier coprecipitate. The results of the toxicity 
studies are summarized in Table XX. The administration of digitoxin as
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TABLE XX
Oral Toxicity of Various Digitoxin 
Preparations in Mice&
Number of
Test System Animals Dead^ Percentage Mortality
Digitoxin 6 20
Digitoxin-Poloxalene 29 97
Coprecipitate
Digitoxin-DCAC 30 100
Coprecipitate
Digitoxin-Poloxalene 11 37
Physical Mixture
Digitoxin-DCAC 9 30
Physical Mixture
Poloxalkold 0 0
DCA® 0 0
^A dose of 70 mg/kg digitoxin was administered as a suspension in 
0.5% methyl cellulose. Thirty animals were used for each test 
system.
bAnimals observed for 7 days post administration.
^A 700 mg/kg dose was administered containing 10% w/w digitoxin. 
^2.7 g/kg dose.
®630 mg/kg dose.
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a coprecipitate with poloxalene caused a significant (p <0.001) increase 
in its oral toxicity. The administration of a physical mixture did not 
result in a significant change in oral toxicity. Administration of up 
to 2.7 g/kg poloxalene alone did not result in any deaths. This is in 
agreement with the reported toxicity for poloxalene (86). Most of the 
mice given toxic doses of the coprecipitated drug died at a much earlier 
time than those dosed with the pure drug or the physical mixture. Wliile 
62% of the deaths resulting from the coprecipitate occurred between 12 
and 36 hours post administration, only 33% of the deaths due to the pure 
drug occurred in 72 hours. The observed increase in the toxicity of 
digitoxin-poloxalene coprecipitate is attributed to an increase in the 
rate and possibly the extent of oral absorption. The markedly higher 
toxicity of the coprecipitated drug as compared to the pure drug does 
not necessarily imply that digitoxin, when administered alone, is less 
available to the body than when administered in the form of the copreci­
pitate. It suggests, however, that the peak level of digitoxin in the 
body after oral administration of the coprecipitate is far higher than 
that achieved following an equal dose of pure drug. Digitoxin is a hy­
drophobic drug which is passively absorbed and whose absorption is rate- 
limited by the rate at which it goes into solution in the GI fluids. In 
this type of absorption pattern, any increase in the rate of solution of 
the drug in the GI fluids would produce a corresponding increase in its 
absorption rate. Since dissolution must precede absorption, a faster 
dissolving form of the drug should be absorbed at a more rapid rate and 
possibly accumulate in the body to a greater extent than an equal dose 
of a slowly dissolving form of the same drug.
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Digitoxin-DCA Coprecipitates. Figure 7 shows the dissolution of digi­
toxin form the DCA test systems. The coprecipitates dissolve much faster 
than the pure drug and the 1% coprecipitate goes into solution more 
rapidly than the 10% preparation, at least in the initial stages. This 
difference could not be due to the bulk effect of the carrier because 
the dissolution of digitoxin from the 10 and 1% physical mixtures pro­
ceeded at almost equal rates. The studies with physical mixtures indi­
cate that the mere presence of the carrier in amounts equivalent to 
those present in the coprecipitates is not responsible for the enhanced 
dissolution of digitoxin from the coprecipitates. Solvate formation 
has already been shown not to effect the dissolution of digitoxin sig­
nificantly. That there is no interaction between digitoxin and DCA was 
shown by the solubility studies (Table XXI),
Therefore, it is proposed that coprecipitating the drug with the
carrier caused the former to crystallize in extremely fine form or to be
present in an amorphous form and that this particle size difference is 
the reason for the faster dissolution and increased solubility of the 
coprecipitated drug.
Both the DCA and poloxalene coprecipitates achieve supersatura­
tion, but there is no indication of drug precipitation and the decline
towards the equilibrium value, as was the case with digitoxin-PVP co­
precipitate reported by Stupak and Bates (107).
A very distinct difference exists in the pattern of dissolution 
of digitoxin-poloxalene (Fig. 6) and digitoxin-DCA coprecipitates (Fig. 7) 
The drug from the poloxalene coprecipitates goes into solution very 
rapidly during the first 30 minutes. After this period there is almost
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Figure 7.— Dissolution rates of digitoxin from deoxycholic acid test 
preparations. Key: ■  , untreated drug; # ,  treated drug; 
A ,  1% and 10% physical mixtures; ^  , 10% coprecipitate;
0 ,  1% coprecipitate.
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TABLE XXI
Effect of Poloxalene and Deoxycholic Acid on 
Solubility of Digitoxin in Water at 37°
Solubility (mg/100 ml) 
Wa t e r .......................................... 0.62
Poloxalene in concentration
equivalent to 10% coprecipitate ............  0.61
Poloxalene in concentration
equivalent to 1% coprecipitate ............  0.60
Deoxycholic acid in concentration
equivalent to 10% coprecipitate ..............  0.61
Deoxycholic acid in concentration
equivalent to 1% coprecipitate ............... 0.64
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no change in the amount of the drug in solution. In contrast, the DCA 
coprecipitates release digitoxin over a greater length of time. This 
difference in the release pattern of the drug could be due to the dif­
ferences in the solubility of the two carriers in water. Since polox­
alene is highly soluble, it dissolves rapidly and all the drug dispersed 
in it comes in contact with the dissolution medium. On the other hand, 
DCA, because of its low solubility, does not let all the dispersed drug 
come in contact with the dissolution medium immediately.
The shape of the dissolution curves of the DCA coprecipitates 
(Fig. 7) suggests one or the other of the following. The initial steeply 
rising portion may represent the dissolution of the drug present on the 
surface of the carrier or it may represent the dissolution of a high 
energy (amorphous) form of the drug. Once this surface-dispersed or 
high-energy form dissolves, the dissolution is rate-limited by the leach­
ing out of the drug present in the interior of the carrier or by the 
erosion of the drug crystals.
The oral toxicity studies of digitoxin-DCA test preparations are 
summarized in Table XX. The administration of digitoxin as a coprecipi­
tate with deoxycholic acid caused a significant (p <0.001) increase in 
oral toxicity. Once again the mice which received the coprecipitate 
died much sooner than those dying from the physical mixture. Of thirty 
mice which received plain DCA in amounts equivalent to that present in 
the coprecipitate, none died. The inherent toxicity of DCA is therefore 
not a contributing factor to the enhanced toxicity of the coprecipitated 
drug which seems to be due to an increase in the rate at which the drug 
is absorbed from the coprecipitate.
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In Vitro~ln Vivo Correlation. A linear relationship was found to exist 
between the amount of digitoxin in solution (from the poloxalene and DCA 
preparations) at all sampling times and the number of deaths in seven 
days. As an example, the correlation between the amount of digitoxin. 
dissolved at the 60 minute period and toxicity is plotted in Figure 8. 
The line of best fit was drawn by the method of least squares and the 
corresponding equation and the r value is given below: 
y = 4.6357 x + 3.9735
r = 0.9976
Digoxin-Poloxalene Coprecipitates. The dissolution characteristics of 
digoxin from poloxalene test systems are illustrated in Figure 9 and 
Table XXII. The coprecipitates dissolve significantly faster than the 
pure drug and the 1% coprecipitate dissolves faster than the 10% copre­
cipitate. It was found that precipitating digoxin from ethanol did not 
significantly alter the dissolution of the drug. Though the physical 
mixtures show a significant enhancement of drug dissolution, there was 
no difference between the 10 and 1% mixtures. Equilibrium solubility 
studies (Table XXIII) indicate that poloxalene increases drug solubility 
to a small extent. It is evident, however, that though the surface 
tension-lowering and solubilizing effect of poloxalene do contribute to 
the enhanced dissolution of the coprecipitated drug, these effects do 
not fully account for the differences in dissolution of the pure and 
coprecipitated drug. It is probable, therefore, that coprecipitation 
causes the drug to be present as fine particles and in a finer form in 
the 1% coprecipitate, resulting in faster drug dissolution.
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Figure 8.--Correlation between the amount of digitoxin in solution at 
60 minutes and the number of mice dead in 7 days. Key;
0  , pure drug; A  , physical mixture with CCA; O , physical 
mixture with poloxalkol; A  , DCA coprecipitate; ^ , polox­
alene coprecipitate.
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Figure 9.— Dissolution rates of digoxin from poloxalene test
preparations. Key: #  , treated drug; □  , untreated drug; 
A >  1% and 10% physical muxtures; ©  , 10% coprecipitated; 
0 ,  1% coprecipitated.
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Dissolution Rate Studies of Digoxin 
Test Preparations in Water at 37"
Concentration of Digoxin^ (yg/ml) in Solution from
Test Systems
Time (minutes) I II III IV V VI VII VIII IX X
30 0.83 2.68 19.30 7.02 29.55 7.02 3.84 6.33 13.14 6.98
60 1.37 4.08 22.40 9.75 29.87 9.75 5.15 8.24 14.91 8.43
90 1.88 5.10 23.66 11.25 30.00 11.25 6.02 9.21 16.11 9.20
120 2.37 6.02 24.41 12.25 30.00 12.25 6.48 9.90 16.96 10.05
150 2.84 6.80 24.94 12.91 30.00 12.91 7.04 10.54 17.44 10.35
180 3.27 7.53 25.58 13.29 30.00 13.29 7.26 10.70 18.04 10.80
I Treated drug 
II Untreated drug
III 10% coprecipitate with poloxalene 
IV 10% physical mixture with poloxalene 
V 1% coprecipitate with poloxalene
^Mean of two experiments
VI 1% physical mixture with poloxalene 
VII 10% coprecipitate with deoxycholic acid
VIII 10% physical mixture with deoxycholic 
acid
IX 1% coprecipitate with deoxycholic acid
X 1% physical mixture with deoxycholic 
acid toK)
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TABLE XXIII
Effect of Poloxalene and Deoxycholic Acid 
on Solubility of Digoxin in Water at 37°
Solubility (mg/100 ml) 
W a t e r .......................................... 3.47
Poloxalene in concentration
equivalent to 10% coprecipitate ............  4.77
Poloxalene in concentration
equivalent to 1% coprecipitate ............  5.38
Deoxycholic acid in concentration
equivalent to 10% coprecipitate ............  4.62
Deoxycholic acid in concentration
equivalent to 1% coprecipitate ............  4.25
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Table XXIV summarizes the results of the oral toxicity studies. 
Digoxin-poloxalene coprecipitate was no more toxic to mice than the plain 
drug. This finding indicates at least in the case of oral toxicity 
studies, that dissolution and oral absorption do not always correlate.
It is probable that the interaction between the drug and the carrier has 
a negative effect on the oral absorption of the drug.
Digoxin-DCA Coprecipitates. The dissolution of digoxin from DCA copre­
cipitates (Fig. 10) proceeds at a faster rate compared to the dissolution 
of the pure drug. The physical mixtures also dissolve faster than the 
drug. The dissolution of the drug from both physical mixtures proceeds 
at a rate that is higher than its dissoluiton from the 10% coprecipitate. 
Equilibrium solubility studies (Table XXIII) indicate a possible inter­
action between digoxin and DCA. It seems that the presence of an extra 
hydroxyl group in digoxin (compared to digitoxin) results in molecular 
interaction between the drug and both the carriers. The oral toxicity 
in mice of the 10% digoxin-DCA coprecipitate (Table XXIV) did not signi­
ficantly increase beyond that of plain DCA (in the amount present in the 
coprecipitate). It is probable that the toxicity of the plain carrier 
is masking any increase in oral absorption, and hence toxicity, of the 
coprecipitate. It is also possible that the interaction between the 
drug and the carrier, which is indicated by the solubility studies, has 
a negative effect on the oral absorption of the drug.
Effect of Aging on the Dissolution of Coprecipitated Drugs. It was found 
by Chiou and Niazi (19) that an aged sample of sulfathiazole-urea solid 
dispersion dissolved at a slower rate than the freshly prepared sample.
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TABLE XXIV
Oral Toxicity of Various Digoxin 
Preparations in Mice^
Test System 
Digoxin
Di goxin-Poloxalene 
Coprecipitate
Digoxin-DCA^
Coprecipitate
Digoxin-Poloxalene 
Physical Mixture
Digoxin-DC A<̂
Physical Mixture
DCA^
Number of 
Animals Dead^
1
0
30
26
27
Percentage Mortality 
3 
0
100
87
90
^Dose of 300 mg/kg digoxin was administered as a suspension in
0.5% methyl cellulose. Thirty animals were used for each test 
system.
^Animals observed for 7 days post administration.
‘'A 3 g/kg dose was administered containing 10% w/w digoxin.
^2.7 g/kg dose.
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Figure 10.— Dissolution rates of digoxin from deoxycholic acid test 
preparations. Key: 0  , treated drug; , 10% copreci­
pitate; A  , 1% and 10% physical mixtures; 0 ,  1% 
coprecipitate; □  , untreated drug.
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The effect of aging on the dissolution of some digitoxin preparations is 
shown in Figure 11 and Table XXV and that of some digoxin preparations 
is shown in Figure 12 and Table XXVI.
X-Ray Diffraction Studies. The x-ray diffraction technique was used to 
find if the drugs and the carriers had undergone crystalline modifica­
tions due to treatment by the solvent. The diffraction spectra of 
treated digitoxin and treated DCA were found to be different from those 
of the untreated samples and are presented in Figures 13 and 14 respec­
tively. No differences in the diffraction patterns of digoxin and polox­
alene were noted due to treatment with ethanol.
The x-ray diffraction technique has been used by some authors 
(18, 20, 21) to study the nature of solid dispersions obtained. In this 
study, the coprecipitates gave the diffraction patterns of the carriers 
only, as did the physical mixtures. Though the x-ray studies do not 
rule out the formation of solid solutions or the presence of the drug in 
an amorphous form in the coprecipitates, the x-rays do not confirm any 
of these possibilities either, because simple dilution with the carrier 
masked the diffraction peaks of the drug.
SUMMARY
The influence of two medicinal surfactants, poloxalene and di- 
octylsodium sulfosuccinate on the dissolution behavior of sulfisoxazole 
and sulfadiazine in pH 6 buffer was investigated. A dramatic increase 
in the dissolution rate of both the drugs was observed in the presence 
of all concentrations of the surfactants. The effect of the surfactants
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Figure 11.--Effect of aging on the dissolution rates of digitoxin 
coprecipitates. Key: A  , 10% coprecipitate with 
poloxalene kept at room temperature for 152 days;
freshly made 10% coprecipitate with poloxalene; 
Q ,  10% coprecipitate with deoxycholic acid kept at 
room temperature for 146 d a y s ; Q  , freshly made 10< 
coprecipitate with deoxycholic acid.
'%
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TABLE XXV
Effect of Aging on the Dissolution of 
Digitoxin Test Preparations
Concentration of Digitoxin (yg/ml) 
in Solution from 
Test Systems
(minutes) I II III IV
30 10.44 7.26 7.32 4.34
60 10.95 7.70 10.99 8.66
90 11.18 7.78 13.98 11.73
120 11. 23 7.85 16.13 13.76
150 11.53 7.93 17.41 15.70
180 11.45 8.01 19. 81 16.84
Freshly made 10% coprecipitate with poloxaleneI
II Test System I kept at room temperature for 152 days. 
Ill Freshly made 10% coprecipitate with deoxycholic acid. 
IV Test System III kept at room temperature for 146 days.
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Figure 12.--Effect of aging on the dissolution rates of digoxin co­
precipitates. Key: Q  , 1% coprecipitate with deoxy­
cholic acid kept at room temperature for 73 days;
0 ,  freshly made 1% coprecipitate with deoxycholic 
acid; C) » 1% coprecipitate with poloxalene kept at room 
temperature for 79 days; (%) , freshly made 1% coprecipi­
tate with poloxalene.
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TABLE XXVI
Effect of Aging on the Dissolution of 
Digoxin Test Preparations
Concentration of Digoxin (yg/ml) 
in Solution from 
Test Systems
(minutes) 1 11 111 IV
30 29.55 22.56 13.14 1.16
60 29.87 22.79 14.91 2.02
90 30.00 23.01 16.11 2.70
120 30.00 23.24 16.96 3.30
150 30.00 23.46 17.44 3.75
180 30.00 23.69 18.04 4. 08
I Freshly made 1% coprecipitate with poloxalene.
II Test System 1 kept at room temperature for 79 days. 
Ill Freshly made 1% coprecipitate with deoxycholic acid. 
IV Test System 111 kept at room temperature for 73 days.
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Figure 13.--X-ray diffraction spectra of treated (top) and untreated
(bottom) digitoxin.
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Figure 14.--X-ray diffraction spectra of untreated (top) and treated
(bottom) deoxycholic acid.
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on the absorption of the two sulfonamides from rat intestinal loops was 
also studied. A significant but less dramatic increase in absorption 
was noted. Dissolution rate and absorption could be correlated only 
qualitatively. The two surfactants had no effect on the amount of sul­
fisoxazole excreted by the rat in 24 hours.
Solid dispersions of the cardiac glycosides digitoxin and digoxin 
in two inert carriers, poloxalene and deoxycholic acid were prepared by 
the solvent method in a 1:9 and 1:99 (w/w) ratio. A significant improve­
ment in dissolution rates was observed with all solid dispersions with 
the exception of the 1:9 digoxin-deoxycholic acid system. In all cases, 
the 1:99 solid dispersions dissolved at a faster rate than the 1:9 solid 
dispersions. Biological work in mice indicated that the 1:9 digitoxin 
poloxalene and digitoxin-deoxycholic acid systems to be significantly 
potent than either the pure drug or physical mixtures. The difference 
in potency of the 1:9 digoxin-poloxalene solid dispersion was not signi­
ficantly different from the control, although the dissolution of the 
former was four to six times more rapid in in vitro experiments. Results 
suggest that no generalizations can be made about the efficacy of solid 
dispersions and that dissolution rate data when used by itself, without 
complimenting biological work might be misleading. The x-ray diffraction 
technique did not conclusively prove the nature of the drug in the copre­
cipitates.
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